documents incorporated reference parts portions registrants proxy statement annual meeting shareholders filed within days close iii registrants fiscal year proxy statement incorporated reference report reportitem part business general segments business geographic areas raw materials patents trademarks seasonality competition environment regulation available information risk factors b unresolved staff comments properties legal proceedings mine safety disclosures executive officers registrant part ii market registrants common equity related stockholder matters issuer purchases equity securities selected financial data managements discussion analysis results operations financial condition quantitative qualitative disclosures market risk financial statements supplementary data changes disagreements accountants accounting financial disclosure controls procedures b information part iii directors executive officers corporate governance executive compensation security ownership certain beneficial owners management related stockholder matters certain relationships related transactions director independence principal accountant fees services part iv exhibits financial statement schedules summary signatures exhibit index cautionary note regarding forwardlooking statements annual report johnson johnson 's publicly available documents contain forwardlooking statements within meaning safe harbor provisions us private securities litigation reform act management representatives johnson johnson subsidiaries company also may time time make forwardlooking statements forwardlooking statements relate strictly historical current facts reflect managements assumptions views plans objectives projections future forwardlooking statements may identified use words plans expects anticipates estimates words similar meaning conjunction among things discussions future operations expected operating results financial performance impact planned acquisitions dispositions companys strategy growth product development regulatory approvals market position expenditures forwardlooking statements based current beliefs expectations assumptions regarding future events subject uncertainties risks changes difficult predict many outside company 's control investors realize underlying assumptions prove inaccurate known unknown risks uncertainties materialize companys actual results financial condition could vary materially expectations projections expressed implied forwardlooking statements investors therefore cautioned rely forwardlooking statements risks uncertainties include limited risks related product development market success competition challenges uncertainties inherent innovation development new improved products technologies companys continued growth success depend including uncertainty clinical outcomes additional analysis existing clinical data obtaining regulatory approvals health plan coverage customer access initial continued commercial success challenges companys ability obtain protect adequate patent intellectual property rights new existing products technologies united states important markets impact patent expirations typically followed introduction competing biosimilars generics resulting revenue market share losses increasingly aggressive frequent challenges companys patents competitors others seeking launch competing generic biosimilar products increased receptivity courts united states patent trademark office decision makers challenges potentially resulting loss market exclusivity rapid decline sales relevant product sooner expected competition research development new improved products processes technologies result product process obsolescence competition reach agreement third parties collaboration licensing development marketing agreements products technologies competition based costeffectiveness product performance technological advances patents attained competitors allegations companys products infringe patents intellectual property rights third parties could adversely affect companys ability sell products question require payment money damages future royalties risks related product liability litigation regulatory activity product efficacy safety concerns whether based scientific evidence potentially resulting product withdrawals recalls regulatory action part united states food drug administration international counterparts declining sales reputational damage increased litigation expense share price impact impact including declining sales reputational damage significant litigation government action adverse company including product liability claims allegations related pharmaceutical marketing practices contracting strategies impact adverse judgment settlement adequacy reserves related legal proceedings including patent litigation product liability personal injury claims securities class actions government investigations employment legal proceedings increased scrutiny health care industry government agencies state attorneys general resulting investigations prosecutions carry risk significant civil criminal penalties including limited debarment government business failure meet compliance obligations mcneilppc inc consent decree compliance agreements governments government agencies could result significant sanctions potential changes applicable laws regulations affecting united states international operations including relating approval new products licensing patent rights sales promotion health care products access reimbursement pricing health care products services environmental protection sourcing raw materials compliance local regulations laws may restrict companys ability manufacture sell products relevant markets including requirements comply medical device reporting regulations requirements european union 's medical devices regulation changes domestic international tax laws regulations including changes related tax cuts jobs act united states federal act tax reform ahv financing switzerland increasing audit scrutiny tax authorities around world exposures additional tax liabilities potentially excess existing reserves issuance new revised accounting standards financial accounting standards board regulations securities exchange commission risks related companys strategic initiatives healthcare market trends pricing pressures resulting trends toward health care cost containment including continued consolidation among health care providers market participants trends toward managed care shift toward governments increasingly becoming primary payers health care expenses significant new entrants health care markets seeking reduce costs government pressure companies voluntarily reduce costs price increases restricted spending patterns individual institutional governmental purchasers health care products services due economic hardship budgetary constraints challenges companys ability realize strategy growth including externally sourced innovations development collaborations strategic acquisitions licensing marketing agreements potential heightened costs external arrangements due competitive pressures potential expected strategic benefits opportunities planned completed acquisition divestiture company may realized may take longer realize expected potential expected benefits opportunities related past ongoing restructuring actions may realized may take longer realize expected risks related economic conditions financial markets operating internationally impact inflation fluctuations interest rates currency exchange rates potential effect fluctuations revenues expenses resulting margins potential changes exportimport trade laws regulations policies united states countries including increased trade restrictions tariffs potential drug reimportation legislation impact international operations financial instability international economies sovereign risk possible imposition governmental controls restrictive economic policies unstable international governments legal systems changes global climate extreme weather natural disasters could affect demand company 's products services cause disruptions manufacturing distribution networks alter availability goods services within supply chain affect overall design integrity company 's products operations impact armed conflicts terrorist attacks united states parts world including social economic disruptions instability financial markets risks related supply chain operations difficulties delays manufacturing internally third party providers otherwise within supply chain may lead voluntary involuntary business interruptions shutdowns product shortages withdrawals suspensions products market potential regulatory action interruptions breaches company 's information technology systems company 's vendors could result reputational competitive operational business harm well financial costs regulatory action reliance global supply chains production distribution processes complex subject increasing regulatory requirements may adversely affect supply sourcing pricing materials used companys products potential expected benefits opportunities related restructuring actions contemplated global supply chain including company 's transaction jabil may realized may take longer realize expected including due required approvals applicable regulatory authorities disruptions associated announced global supply chain actions may adversely affect supply sourcing materials used company 's products investors also carefully read risk factors described item annual report description certain risks could among things cause companys actual results differ materially expressed forwardlooking statements investors understand possible predict identify factors consider risks described item complete statement potential risks uncertainties company undertake publicly update forwardlooking statement may made time time whether result new information future events developmentspart item business general johnson johnson subsidiaries company approximately employees worldwide engaged research development manufacture sale broad range products health care field johnson johnson holding company operating companies conducting business virtually countries world companys primary focus products related human health wellbeing johnson johnson incorporated state new jersey executive committee johnson johnson principal management group responsible strategic operations allocation resources company committee oversees coordinates activities company 's three business segments consumer pharmaceutical medical devices within strategic parameters provided committee senior management groups us international operating companies responsible strategic plans daytoday operations companies subsidiary within business segments limited exceptions managed residents country located segments business company organized three business segments consumer pharmaceutical medical devices additional information required item incorporated herein reference narrative tabular descriptions segments operating results item managements discussion analysis results operations financial condition report note segments business geographic areas notes consolidated financial statements included item report consumer consumer segment includes broad range products focused personal healthcare used beauty overthe counter pharmaceutical baby care oral care womens health wound care markets major brands beauty include aveeno clean clear dr cilabo neutrogena ogx product lines overthecounter medicines include broad family tylenol acetaminophen products sudafed cold flu allergy products benadryl zyrtec allergy products motrin ib ibuprofen products nicorette smoking cessation products outside us zarbees naturals pepcid line acid reflux products baby care includes johnsons aveeno baby line products oral care includes listerine product line major brands womens health outside north america stayfree carefree sanitary pads ob tampon brands wound care brands include bandaid brand adhesive bandages neosporin first aid product lines products marketed general public sold online retail outlets distributors throughout world pharmaceutical pharmaceutical segment focused six therapeutic areas immunology eg rheumatoid arthritis inflammatory bowel disease psoriasis infectious diseases eg hivaids neuroscience eg mood disorders neurodegenerative disorders schizophrenia oncology eg prostate cancer hematologic malignancies cardiovascular metabolism eg thrombosis diabetes pulmonary hypertension eg pulmonary arterial hypertension medicines segment distributed directly retailers wholesalers hospitals health care professionals prescription use key products pharmaceutical segment include remicade infliximab treatment number immunemediated inflammatory diseases simponi golimumab subcutaneous treatment adults moderate severe rheumatoid arthritis active psoriatic arthritis active ankylosing spondylitis moderately active severely active ulcerative colitis simponi aria golimumab intravenous treatment adults moderate severe rheumatoid arthritis active psoriatic arthritis active ankylosing spondylitis stelara ustekinumab treatment adults children moderate severe plaque psoriasis adults active psoriatic arthritis adults moderately severely active crohn 's disease treatment moderately severely active ulcerative colitis tremfya guselkumab treatment adults moderate severe plaque psoriasis edurant rilpivirine prezista darunavir prezcobixrezolsta darunavircobicistat antiretroviral medicines treatment human immunodeficiency virus hiv combination antiretroviral products symtuza darunavircobicistatemtricitabinetenofovir alafenamide oncedaily single tablet regimen treatment hiv concerta methylphenidate hcl extendedrelease tablets cii treatment attention deficit hyperactivity disorder invega sustennaxeplion paliperidone palmitate treatment schizophrenia schizoaffective disorder adults invega trinzatrevicta paliperidone palmitate treatment schizophrenia patients adequately treated invega sustenna least four months risperdal consta risperidone longacting injection treatment schizophrenia themaintenance treatment bipolar disorder adults zytiga abiraterone acetate treatment metastatic castration resistant prostate cancer crpc metastatic highrisk castrationsensitive prostate cancer imbruvica ibrutinib treatment certain bcell malignancies blood cancers chronic graft versus host disease waldenstrm 's macroglobulinemia darzalex daratumumab treatment relapsedrefractory multiple myeloma velcade bortezomib treatment multiple myeloma mantle cell lymphoma procriteprex epoetin alfa treatment chemotherapyinduced anemia patients chronic kidney disease xarelto rivaroxaban oral anticoagulant prevention deep vein thrombosis dvt may lead pulmonary embolism pe patients undergoing hip knee replacement surgery reduce risk stroke systemic embolism patients nonvalvular atrial fibrillation treatment reduction risk recurrence dvt pe invokana canagliflozin treatment adults type diabetes invokametvokanamet canagliflozinmetformin hcl combination therapy fixed doses canagliflozin metformin hydrochloride treatment adults type diabetes invokamet xr canagliflozinmetformin hydrochloride extendedrelease oncedaily fixeddose combination therapy canagliflozin metformin hydrochloride extendedrelease treatment adults type diabetes opsumit macitentan monotherapy combination indicated longterm treatment pulmonary arterial hypertension pah uptravi selexipag approved oral selective ip receptor agonist targeting prostacyclin pathway pah many medicines developed collaboration strategic partners licensed companies maintain active lifecycle development programs medical devices medical devices segment includes broad range products used orthopaedic surgery interventional solutions cardiovascular neurovascular eye health fields products distributed wholesalers hospitals retailers used principally professional fields physicians nurses hospitals eye care professionals clinics include orthopaedic products general surgery biosurgical endomechanical energy products electrophysiology products treat cardiovascular disease vision products disposable contact lenses ophthalmic products related cataract laser refractive surgery geographic areas johnson johnson subsidiaries company approximately employees worldwide engaged research development manufacture sale broad range products health care field company conducts business virtually countries world primary focus products related human health wellbeing products made sold international business include many described segments business consumer pharmaceutical medical devices however principal markets products methods distribution international business vary country culture products sold international business include developed us subsidiaries abroad investments activities countries outside us subject higher risks comparable us activities investment commercial climate may influenced financial instability international economies restrictive economic policies political legal system uncertainties raw materials raw materials essential company 's business generally readily available multiple sources exceptions temporary unavailability raw materials would likely material adverse effect financial results company patents company 's subsidiaries made practice obtaining patent protection products processes possible licensed significant number patents us countries relating products product uses formulations manufacturing processes aggregate believed material importance company operation businesses companys subsidiaries face patent challenges third parties including challenges seeking manufacture market generic biosimilar versions company 's key pharmaceutical products prior expiration applicable patents covering products significant legal proceedings claims involving company 's patent intellectual property described note legal proceedings intellectual property notes consolidated financial statements included item report sales companys largest product stelara ustekinumab accounted approximately company 's total revenues fiscal accordingly patents related product believed material thecompany one set granted patents related specifically stelara set patents owned janssen biotech inc whollyowned subsidiary johnson johnson patents force us many countries outside us us latest projected expiration date patents set due patent term extension adjustment europe latest projected expiration date patents set due supplementary protection certificate patent term extension countries latest projected expiration date addition competing immunology market stelara company currently marketing simponi golimumab simponi aria golimumab next generation immunology products patents related products force latest projected us expiration date due patent term extension adjustment company also markets remicade infliximab immunology market companys nd largest product patents product expired food drug administration approved first infliximab biosimilar sale us number products launched since extensive description legal matters regarding patents related remicade see note legal proceedings intellectual property pharmaceutical remicade related cases notes consolidated financial statements included item report trademarks companys subsidiaries made practice selling products trademarks obtaining protection trademarks available means trademarks protected registration us countries products marketed company considers trademarks aggregate material importance operation businesses seasonality worldwide sales reflect significant degree seasonality however spending heavier fourth quarter year quarters reflects increased spending decisions principally advertising research development activity competition product lines company 's subsidiaries compete companies locally globally competition exists product lines without regard number size competing companies involved competition research internally externally sourced involving development improvement new existing products processes particularly significant development new innovative products well protecting underlying intellectual property companys product portfolio important company 's success areas business competitive environment requires substantial investments continuing research addition development maintenance customer demand companys consumer products involve significant expenditures advertising promotion environment company subject variety us international environmental protection measures company believes operations comply material respects applicable environmental laws regulations companys compliance requirements change past year expected material effect upon capital expenditures cash flows earnings competitive position regulation companys businesses subject varying degrees governmental regulation countries operations conducted general trend toward increasingly stringent regulation enforcement subject costly complex us foreign laws governmental regulations adverse regulatory action may materially adversely affect financial condition business operations us drug device cosmetic industries long subject regulation various federal state agencies primarily product safety efficacy manufacturing advertising labeling safety reporting exercise broad regulatory powers us food drug administration fda continues result increases amounts testing documentation required fda approval new drugs devices corresponding increase expense product introduction similar trends also evident major markets outside us new medical device regulatory framework new privacy regulations europe countries examples increased regulation regulatory agencies whose purview company operates administrative powers may subject actions product withdrawals recalls seizure products civil criminal sanctions cases thecompanys subsidiaries may deem advisable initiate product recalls fda regulatory agencies around globe also increasing enforcement activities us fda conclude compliance applicable laws regulations drugs medical devices ineffective pose unreasonable health risk us fda could ban products detain seize adulterated misbranded products order recall repair replacement refund products refuse grant pending applications marketing authorization require certificates foreign governments exports andor require us notify health professionals others products present unreasonable risks substantial harm public health us fda may also assess civil criminal penalties us officers employees impose operating restrictions companywide basis enjoin andor restrain certain conduct resulting violations applicable law us fda may also recommend prosecution us department justice adverse regulatory action depending magnitude may restrict us effectively marketing selling products limit ability obtain future clearances approvals could result substantial modification business practices operations equivalent enforcement mechanisms exist different countries conduct business costs human health care continue subject study investigation regulation governmental agencies legislative bodies around world us attention focused states regulatory agencies congress drug prices profits programs encourage doctors write prescriptions particular drugs recommend use purchase particular medical devices increased focus interactions healthcare companies health care providers various transparency laws regulations require disclosures financial relationships companies health care providers payers become potent force market place increased attention paid drug medical device pricing appropriate drug medical device utilization quality costs health care generally us government agencies continue efforts repeal modify provisions patient protection affordable care act aca passed example federal legislation repealed acas individual mandate tax penalty well tax generous employersponsored healthcare plans cms began permitting states impose work requirements persons covered medicaid expansion plans certain federal subsidies insurers ended certain shortterm insurance plans offering full array aca benefits allowed extend duration changes challenged us courts longterm impact remains uncertain us government also continues propose implement changes medicare part benefit including size manufacturer discounts coverage gap catastrophic phases benefit changing federal landscape positive negative impacts us healthcare industry much remaining uncertain various provisions federal law potential modification repeal laws ultimately affect industry addition business practices health care industry come increased scrutiny particularly us government agencies state attorneys general resulting investigations prosecutions carry risk significant civil criminal penalties company relies global supply chains production distribution processes complex subject increasing regulatory requirements may faced unexpected changes resulting brexit may affect sourcing supply pricing materials used company 's products processes also subject complex lengthy regulatory approvals available information companys main corporate website address wwwjnjcom companys sec filings also available companys website wwwinvestorjnjcomseccfm soon reasonably practicable electronically filed furnished sec sec filings also available secs website wwwsecgov investors public note company also announces information wwwfactsaboutourprescriptionopioidscom wwwfactsabouttalccom use websites communicate investors public products litigation matters possible information post websites could deemed material information therefore encourage investors others interested company review information posted websites conjunction wwwjnjcom company'ssec filings press releases public conference calls webcasts addition restated certificate incorporation bylaws written charters audit committee compensation benefits committee nominating corporate governance committee regulatory compliance committee science technology sustainability committee board directors companys principles corporate governance code business conduct employees code business conduct ethics members board directors executive officers corporate governance materials available atwwwinvestorjnjcomgovcfm company 's website provided without charge shareholder submitting written request provided information wwwjnjcom wwwfactsaboutourprescriptionopioidscom wwwfactsabouttalccom deemed part report incorporated filings company makes sec item risk factors company faces number uncertainties risks difficult predict many outside company 's control addition information report companys filings sec investors consider carefully factors set forth investors aware possible predict identify factors following meant complete discussion potential risks uncertainties known unknown risks uncertainties materialize companys business results operations financial condition could adversely affected potentially material way global sales companys pharmaceutical medical devices segments may negatively impacted healthcare reforms increasing pricing pressures sales companys pharmaceutical medical device products significantly affected reimbursements thirdparty payers government healthcare programs private insurance plans managed care organizations part various efforts contain healthcare costs payers putting downward pressure prices products reimbursed us increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries part due continued consolidation among health care providers could result pricing pressures addition increased political scrutiny could result additional pricing pressures outside us numerous major markets including eu japan pervasive government involvement funding healthcare regard directly indirectly impose price controls limit access reimbursement companys products reduce value intellectual property protection company subject significant legal proceedings result significant expenses fines reputational damage ordinary course business johnson johnson subsidiaries subject numerous claims lawsuits involving various issues patent disputes product liability claims product sales marketing pricing practices violate various antitrust unfair trade practices andor consumer protection laws significant proceedings described note legal proceedings notes consolidated financial statements included item report litigation general securities derivative action class action multidistrict litigation particular expensive disruptive matters may include thousands plaintiffs may determined class actions may involve parties seeking large andor indeterminate amounts including punitive exemplary damages may remain unresolved several years example company defendant numerous lawsuits arising use body powders containing talc primarily johnsons baby powder companys sale manufacturing marketing opioidswhile company believes substantial defenses matters feasible predict ultimate outcome litigation company could future required pay significant amounts result settlements judgments matters potentially excess accruals including matters company could held jointly severally liable among defendants resolution increase accruals one matters reporting period could material adverse effect company 's results operations cash flows period furthermore result cost availability factors effective november company ceased purchasing thirdparty product liability insurance product reliability safety effectiveness concerns significant negative impacts sales results operations lead litigation cause reputational damage concerns product safety whether raised internally litigants regulators consumer advocates whether based scientific evidence result safety alerts product recalls governmental investigations regulatory action part fda counterpart countries private claims lawsuits payment fines settlements declining sales reputational damage circumstances also result damage brand image brand equity consumer trust companys products product recalls past could future prompt government investigations inspections shutdown manufacturing facilities continued product shortages related sales declines significant remediation costs reputational damage possible civil penalties criminal prosecution changes tax laws exposures additional tax liabilities could negatively impact companys operating results changes tax laws regulations around world could negatively impact companys effective tax rate results operations change statutory tax rate country would result revaluation companys deferred tax assets liabilities related particular jurisdiction period new tax law enacted change would result expense benefit recorded companys consolidated statement earnings company closely monitors proposals arise countries operates changes statutory tax rate may occur time related expense benefit recorded may material fiscal quarter year law change enactedin fiscal year switzerland enacted federal act tax reform ahv financing traf became effective january december certain cantons company operates yet enacted portions tax reform stipulated swiss federal law enactments future possible guidance applicable taxing authorities may material impact companys operating results see note income taxes additional information company conducts business files tax returns numerous countries addressing tax audits disputes many tax authorities connection organization economic cooperation development base erosion profit shifting beps project companies required disclose information tax authorities operations around world may lead greater audit scrutiny profits earned countries company regularly assesses likely outcomes tax audits disputes determine appropriateness tax reserves however tax authority could take position tax treatment contrary companys expectations could result tax liabilities excess reserves company may able successfully secure defend intellectual property rights essential companys businesses company owns licenses significant number patents proprietary rights determined patent offices courts lawmakers various countries relating products manufacturing processes rights essential companys businesses materially important companys results operations public policy within outside us become increasingly unfavorable toward intellectual property rights company certain obtain adequate patent protection new products technologies us important markets protections granted last long originally anticipated competitors routinely challenge validity extent companys owned licensed patents proprietary rights litigation interferences oppositions proceedings proceedings absorb resources protracted well unpredictable addition challenges companys products infringe patents third parties could result need pay past damages future royalties adversely affect competitive position sales products question company faced increasing patent challenges third parties seeking manufacture market generic biosimilar versions company 's key pharmaceutical products prior expiration applicable patents covering products us manufacturers generic versions innovative human pharmaceutical products may challenge validity claim noninfringement innovator products abbreviated new drug application anda process fda biologics price competition innovation act bpcia enacted created new regulatory pathway approval fda biosimilar alternatives innovatordeveloped biological products also created mechanisms biosimilar applicants challenge patents innovator biologics inter partes review ipr process uspto created america invents act also used competitors challenge patents held companys subsidiaries event company successful defending patents challenges upon atrisk launch despite pending patent infringement litigation generic biosimilar firm product company lose major portion revenues referenced product short period time current legal proceedings involving companys patents intellectual property rights described note legal proceedingsintellectual property notes consolidated financial statements included item report companys businesses operate highly competitive product markets competitive pressures could adversely affect companys earnings company faces substantial competition three operating segments geographic markets companys businesses compete companies sizes basis costeffectiveness technological innovations intellectual property rights product performance real perceived product advantages pricing availability rate reimbursement company also competes market participants securing rights acquisitions collaborations licensing agreements third parties competition rights product candidates technologies may result significant investment acquisition costs onerous agreement terms company competitors development effective less costly products andor ability secure patent intellectual property rights successfully market products ahead company could negatively impact sales companys existing products well ability bring new products market despite significant prior investment related product developmentfor companys pharmaceutical businesses loss patent exclusivity product often followed substantial reduction sales competitors gain regulatory approval generic competing products enter market similar competition triggered loss exclusivity biological product companys medical device businesses technological innovation product quality reputation customer service especially important competitiveness development companies new improved products processes technologies could threaten make companys products technologies less desirable less economical obsolete companys consumer businesses face intense competition branded products retailers privatelabel brands company fails sufficiently differentiate market brand name consumer products could adversely affect revenues profitability products significant challenges delays companys innovation development new products technologies indications could adverse impact companys longterm success companys continued growth success depends ability innovate develop new differentiated products services address evolving health care needs patients providers consumers development successful products technologies also necessary offset revenue losses companys existing products lose market share due various factors competition loss patent exclusivity new products introduced within past five years accounted approximately sales company certain whether able develop license otherwise acquire companies products technologies whether particular product candidates granted regulatory approval approved whether products commercially successful company pursues product development internal research development well collaborations acquisitions joint ventures licensing arrangements third parties contexts developing new products particularly pharmaceutical biotechnology products medical devices requires significant investment resources many years biopharmaceutical research development programs result commercially viable products process depends many factors including ability discern patients health care providers future needs develop promising new compounds strategies technologies achieve successful clinical trial results secure effective intellectual property protection obtain regulatory approvals timely basis reach market successfully differentiate companys products competing products approaches treatment new products enhancements existing products may accepted quickly significantly marketplace due product price competition changes customer preferences healthcare purchasing patterns resistance healthcare providers uncertainty thirdparty reimbursement even following initial regulatory approval success product adversely impacted safety efficacy findings larger real world patient populations well market entry competitive products company faces increasing regulatory scrutiny imposes significant compliance costs exposes company government investigations legal actions penalties like companies healthcare industry company subject extensive regulation investigations legal action national state local government agencies us countries operate regulatory issues regarding compliance good manufacturing practices cgmp comparable quality regulations foreign countries manufacturers drugs devices consumer products lead fines penalties product recalls product shortages interruptions production delays new product approvals litigation addition marketing pricing sale companys products subject regulation investigations legal actions including federal food drug cosmetic act medicaid rebate program federal state false claims acts state unfair trade practices acts consumer protection laws increased scrutiny health care industry business practices recent years government agencies state attorneys general us resulting investigations prosecutions carry risk significant civil criminal penalties including limited debarment participation government healthcare programs debarment could material adverse effect companys business results operations significant current investigations litigation brought government agencies described note legal proceedingsgovernment proceedings notes consolidated financial statements included item report company faces variety risks associated conducting business internationally companys extensive operations business activity outside us accompanied certain financial economic political risks including listed foreign currency exchange fiscal approximately companys sales occurred outside us approximately europe western hemisphere excluding us asiapacific africa region changes nonus currencies relative us dollar impact companys revenues expenses thecompany uses financial instruments mitigate impact fluctuations currency exchange rates cash flows unhedged exposures continue subject currency fluctuations addition weakening strengthening us dollar may result significant favorable unfavorable translation effects operating results companys nonus business activity translated us dollars inflation currency devaluation risks company faces challenges maintaining profitability operations economies experiencing high inflation rates company accounted operations argentina beginning fiscal third quarter venezuela highly inflationary prior threeyear cumulative inflation rate surpassed company strives maintain profit margins areas cost reduction programs productivity improvements periodic price increases might experience operating losses result continued inflation addition impact currency devaluations countries experiencing high inflation rates significant currency exchange fluctuations could negatively impact companys operating results illegal importation pharmaceutical products illegal importation pharmaceutical products countries government price controls market dynamics result lower prices may adversely affect companys sales profitability us countries company operates exception limited quantities prescription drugs personal use foreign imports pharmaceutical products illegal current us law however volume illegal imports continues rise ability patients customers obtain lowerpriced imports grown significantly antibribery regulations company subject various federal foreign laws govern international business practices respect payments government officials laws include us foreign corrupt practices act fcpa prohibits us publicly traded companies promising offering giving anything value foreign officials corrupt intent influencing foreign official purpose helping company obtain retain business gain improper advantage companys business heavily regulated therefore involves significant interaction foreign officials also many countries outside us health care providers prescribe human pharmaceuticals employed government purchasers human pharmaceuticals government entities therefore companys interactions prescribers purchasers subject regulation fcpa addition us application enforcement fcpa various jurisdictions company operates laws regulations including uk bribery act aimed preventing penalizing corrupt anticompetitive behavior enforcement activities laws could subject company additional administrative legal proceedings actions could include claims civil penalties criminal sanctions administrative remedies including exclusion health care programs legal social political risks risks inherent conducting business globally include protective economic policies taken governments trade protection measures importexport licensing requirements compliance local regulations laws including countries regulatory requirements restricting companys ability manufacture sell products relevant market diminished protection intellectual property contractual rights certain jurisdictions potential nationalization expropriation companys foreign assets disruptions markets due war armed conflict terrorism social upheavals pandemics interruptions delays manufacturing operations could adversely affect companys business sales reputation companys manufacture products requires timely delivery sufficient amounts complex highquality components materials company 's subsidiaries operate manufacturing facilities well sourcing hundreds suppliers around world company past may future face unanticipated interruptions delays manufacturing internal external supply chain manufacturing disruptions occur many reasons including regulatory action production quality deviations safety issues labor disputes sitespecific incidents fires natural disasters hurricanes severe weather events raw material shortages political unrest terrorist attacks delays difficulties manufacturing result product shortages declines sales reputational impact well significant remediation related costs associated addressing shortage company relies third parties manufacture certain products failure loss third party manufacturer could result delays increased costs may adversely affect business company relies third parties manufacture certain products depend third party manufacturers allocate us portion manufacturing capacity sufficient meet needs produce products acceptable qualityand acceptable manufacturing yields deliver products us timely basis acceptable prices however guarantee third party manufacturers able meet nearterm longterm manufacturing requirements could result lost sales adverse effect business risks associated reliance third parties manufacture products include reliance third party regulatory compliance quality assurance misappropriation companys intellectual property limited ability manage inventory possible breach manufacturing agreement third party possible termination nonrenewal manufacturing agreement third party time costly inconvenient us moreover third party manufacturers suffer damage facilities lose benefits material agreements experience power outages encounter financial difficulties unable secure necessary raw materials suppliers suffer reduction efficiency company may experience significant business disruption event disruption company would need seek source qualified third party manufacturers likely resulting delays increased costs could affect business adversely counterfeit versions products could harm patients negative impact revenues earnings reputation business industry continues challenged vulnerability distribution channels illegal counterfeiting presence counterfeit products growing number markets internet third parties may illegally distribute sell counterfeit versions products meet rigorous manufacturing testing standards distributors patients counterfeit products may visually indistinguishable authentic version counterfeit medicines pose risk patient health safety conditions manufacturedoften unregulated unlicensed uninspected unsanitary sitesas well lack regulation contents industry 's failure mitigate threat counterfeit medicines could adversely impact business reputation impacting patient confidence authentic products potentially resulting lost sales product recalls increased threat litigation addition diversion products authorized market channels may result reduced revenues negatively affect profitability information security incident including cybersecurity breach could negative impact companys business reputation meet business objectives company relies internal information technology systems networks third parties vendors process store sensitive data including confidential research business plans financial information intellectual property personal data may subject legal protection extensive information security cybersecurity threats affect companies globally pose risk security availability systems networks confidentiality integrity availability companys sensitive data company continually assesses threats makes investments increase internal protection detection response capabilities well ensure companys third party providers required capabilities controls address risk date company experienced material impact business operations resulting information cybersecurity attacks however frequently changing attack techniques along increased volume sophistication attacks potential company adversely impacted impact could result reputational competitive operational business harm well financial costs regulatory action company maintains cybersecurity insurance event information security cyber incident however coverage may sufficient cover financial losses item b unresolved staff comments applicable item properties company 's subsidiaries operate manufacturing facilities occupying approximately million square feet floor space manufacturing facilities used industry segments companys business approximately follows square feet segment thousands consumer pharmaceutical medical devices worldwide total within us five facilities used consumer segment five pharmaceutical segment medical devices segment outside us facilities used consumer segment pharmaceutical segment medical devices segment locations manufacturing facilities major geographic areas world follows number square feet geographic area facilities thousands united states europe western hemisphere excluding us africa asia pacific worldwide total addition manufacturing facilities discussed company maintains numerous office warehouse facilities throughout world research facilities also discussed item managements discussion analysis results operations financial condition report company 's subsidiaries generally seek rather lease manufacturing facilities although principally nonus locations leased office warehouse facilities often leased company also engages contract manufacturers company committed maintaining properties good operating condition mcneilppc inc johnson johnson consumer inc mcneilppc continues operate consent decree signed fda governs certain mcneil consumer healthcare manufacturing operations requires mcneilppc remediate facilities operates lancaster pennsylvania fort washington pennsylvania las piedras puerto rico consent decree following fda inspections mcneilppc received notifications fda three manufacturing facilities conformity applicable laws regulations commercial production restarted consent decree receiving notice fda compliance applicable laws regulations three facilities subject fiveyear audit period thirdparty cgmp expert thus thirdparty expert continue reassess sites various times least information regarding lease obligations see note lease commitments notes consolidated financial statements included item report segment information additions property plant equipment contained note segments business geographic areas notes consolidated financial statements included item reportitem legal proceedings information called item incorporated herein reference information set forth note legal proceedings notes consolidated financial statements included item report addition johnson johnson subsidiaries also parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund comparable state local foreign laws primary relief sought cost past andor future remediation item mine safety disclosures applicable executive officers registrant listed executive officers company family relationships executive officers arrangement understanding executive officer person pursuant executive officer selected annual meeting board directors executive officers elected board hold office one year respective successors elected qualified earlier resignation removal information regard directors company including information alex gorsky also executive officer incorporated herein reference material captioned item election directors proxy statement name age position joaquin duato vice chairman executive committeea peter fasolo phd member executive committee executive vice president chief human resources officerb alex gorsky chairman board directors chairman executive committee chief executive officer ashley mcevoy member executive committee executive vice president worldwide chairman medical devicesc thibaut mongon member executive committee executive vice president worldwide chairman consumerd michael e sneed member executive committee executive vice president global corporate affairs chief communication officere paulus stoffels md vice chairman executive committee chief scientific officerf jennifer l taubert member executive committee executive vice president worldwide chairman pharmaceuticalsg michael h ullmann member executive committee executive vice president general counselh kathryn e wengel member executive committee executive vice president chief global supply chain officeri joseph j wolk member executive committee executive vice president chief financial officerj mr j duato joined company janssenfarmaceutica sa spain subsidiary company held executive positions increasing responsibility pharmaceutical sector named company group chairman pharmaceuticals named worldwide chairman pharmaceuticals mr duato became member executive committee named executive vice president worldwide chairman pharmaceuticals july mr duato promoted vice chairman executive committee responsibility company 's pharmaceutical consumer sectors supply chain information technology global services health wellness groupsb dr p fasolo joined company vice president worldwide human resources cordis corporation subsidiary company subsequently named vice president global talent management company left johnson johnson join kohlberg kravis roberts co chief talent officer dr fasolo returned company vice president global human resources became member executive committee april named executive vice president chief human resources officer dr fasolo responsibility global talent recruiting diversity compensation benefits employee relations aspects human resources agenda company c ms mcevoy joined company assistant brand manager mcneil consumer health subsidiary company advancing positions increasing responsibilities appointed company group chairman vision care followed company group chairman consumer medical devices july ms mcevoy promoted executive vice president worldwide chairman medical devices became member executive committee ms mcevoy responsibility surgery orthopaedics interventional solutions eye health businesses across ethicon depuy synthes biosense webster johnson johnson vision mr mongon joined company director marketing vision care group france subsequently held general management positions country manager france belgium north africa managing director latin america president asiapacific mr mongon transitioned pharmaceutical sector global commercial strategy leader neuroscience therapeutic area joining consumer sector company group chairman asiapacific promoted executive vice president worldwide chairman consumer became member executive committee mr mongon responsibility global development johnson johnsons health wellness products solutions beauty otc oral care baby care womens health wound care e mr e sneed joined company marketing assistant personal products company subsidiary company gained increased responsibilities executive positions across global enterprise mr sneed appointed company group chairman consumer north america followed company group chairman vision care franchise became vice president global corporate affairs chief communications officer mr sneed appointed executive vice president global corporate affairs chief communications officer january became member executive committee july leading company 's global marketing communication design philanthropy functions f dr p stoffels rejoined company acquisition tibotec virco nv chief executive officer virco nv chairman tibotec nv appointed company group chairman global virology assumed role company group chairman pharmaceuticals dr stoffels appointed global head research development pharmaceuticals became worldwide chairman pharmaceuticals dr stoffels appointed chief scientific officer became member executive committee dr stoffels named executive vice president chief scientific officer dr stoffels promoted vice chairman executive committee chief scientific officer responsible companys innovation agenda across pharmaceutical medical devices consumer sectors product safety strategy companys global public health strategy g ms j l taubert joined company worldwide vice president johnson johnson pharmaceutical services subsidiary company held several executive positions increasing responsibility pharmaceutical sector appointed company group chairman north america pharmaceuticals became company group chairman americas pharmaceuticals july ms taubert promoted executive vice president worldwide chairman pharmaceuticals became member executive committee ms taubert responsibility immunology infectious diseases neuroscience oncology cardiovascular metabolism pulmonary hypertension businesses throughout janssen h mr h ullmann joined company corporate attorney law department appointed corporate secretary served role time also held various management positions law department named general counsel medical devices diagnostics appointed vice president general counsel became member executive committee april mr ullmann named executive vice president general counsel mr ullmann worldwide responsibility legal government affairs policy global security aviation health care compliance privacy ms k e wengel joined company project engineer engineering supervisor janssen subsidiary company tenure company held variety strategic leadership executive positions across global enterprise roles within operations quality engineering new products information technology technical business functions ms wengel became first chief quality officer company promoted vice president johnson johnson supply chain july promoted executive vice president chief global supply chain officer became member executivecommittee j mr j j wolk joined company finance manager business development orthomcneil subsidiary company years held variety senior leadership roles several segments functions across company 's subsidiaries pharmaceuticals medical devices supply chain served vice president finance chief financial officer janssen pharmaceutical companies johnson johnson mr wolk became vice president investor relations july appointed executive vice president chief financial officer became member executive committee mr wolk plays strategic role overall management company leads development execution company 's global longterm financial strategy part ii item market registrants common equity related stockholder matters issuer purchases equity securities february record holders common stock company additional information called item incorporated herein reference following sections report note common stock stock option plans stock compensation agreements notes consolidated financial statements included item item security ownership certain beneficial owners management related stockholder matters equity compensation plan information issuer purchases equity securities december company announced board directors approved share repurchase program authorizing company purchase billion company 's common stock share repurchases take place time time open market privately negotiated transactions repurchase program completed fiscal third quarter following table provides information respect common stock purchases company fiscal fourth quarter common stock purchases open market made part systematic plan meet needs companys compensation programs repurchases also include stockforstock option exercises settled fiscal fourth quarter total number maximum number shares units approximate dollar purchased value shares total number part publicly units may yet shares avg price announced plans purchased fiscal period purchased paid per share programs plans programs september october october november november december total fiscal fourth quarter company repurchased aggregate shares johnson johnson common stock openmarket transactions shares purchased openmarket transactions part systematic plan meet needs companys compensation programs september share repurchase program completed aggregate shares purchased total billion since inception repurchase program announced december item selected financial data summary operations statistical data dollars millions except per share amounts sales customers us sales customers international total sales cost products sold selling marketing administrative expenses research development expense inprocess research development interest income interest expense net portion capitalized income expense net restructuring earnings provision taxes income provision taxes income net earnings add net loss attributable noncontrolling interest net earnings attributable johnson johnson percent sales customers diluted net earnings per share common stock percent return average shareholders equity percent increase decrease previous year sales customers diluted net earnings per share nm supplementary balance sheet data property plant equipment net additions property plant equipment total assets longterm debt operating cash flow common stock information dividends paid per share shareholders equity per share market price per share yearend close average shares outstanding millions basic diluted employees thousands attributable johnson johnson nm meaningful item managements discussion analysis results operations financial condition organization business segments description company business segments johnson johnson subsidiaries company approximately employees worldwide engaged research development manufacture sale broad range products health care field company conducts business virtually countries world primary focus products related human health wellbeing company organized three business segments consumer pharmaceutical medical devices consumer segment includes broad range products used baby care oral care beauty overthecounter pharmaceutical womens health wound care markets products marketed general public sold retail outlets distributors throughout world pharmaceutical segment focused six therapeutic areas including immunology infectious diseases neuroscience oncology pulmonary hypertension cardiovascular metabolic diseases products segment distributed directly retailers wholesalers hospitals health care professionals prescription use medical devices segment includes broad range products used orthopaedic surgery interventional solutions cardiovascular neurovascular eye health fields products distributed wholesalers hospitals retailers used principally professional fields physicians nurses hospitals eye care professionals clinics executive committee johnson johnson principal management group responsible strategic operations allocation resources company committee oversees coordinates activities consumer pharmaceutical medical devices business segments product lines company competes companies locally globally throughout world competition exists product lines without regard number size competing companies involved competition research involving development improvement new existing products processes particularly significant development new innovative products well protecting underlying intellectual property company 's product portfolio important companys success areas business competitive environment requires substantial investments continuing research addition development maintenance customer demand companys consumer products involves significant expenditures advertising promotion managements objectives credo foundation companys purpose blend heart science ingenuity profoundly change trajectory health humanity company committed bringing full breadth depth ensure health people today future generations united around common ambition company poised fulfill purpose successfully meet demands rapidly evolving markets competes company broadly based human healthcare committed creating value developing accessible high quality innovative products services new products introduced within past five years accounted approximately sales billion invested research development billion spent acquisitions reflecting managements commitment create lifeenhancing innovations create value partnerships profoundly change trajectory health humanity critical driver companys success diverse employees worldwide employees empowered inspired lead companys credo purpose guides allows every employee use companys reach size advance company 's purpose also lead agility urgency leveraging extensive resources across enterprise enables company innovate execute excellence ensures company remain focused addressing unmet needs society every day invest enduring impact ultimately delivering value patients consumers healthcare professionals employees communities shareholders chartaabbajpg chartfebddaeadjpgresults operations analysis consolidated sales discussion results operations financial condition pertaining fiscal years see companys annual report fiscal year ended december item management 's discussion analysis results operations financial condition worldwide sales increased billion compared increase sales changes consisted following sales increasedecrease due volume price currency total net impact acquisitions divestitures worldwide sales growth negative impact positive impact sales us companies billion billion represents increases sales international companies billion billion represents increase fiveyear compound annual growth rates worldwide us international sales respectively tenyear compound annual growth rates worldwide us international sales respectively sales companies europe experienced sales decline compared prior year included operational growth offset negative currency impact sales companies western hemisphere excluding us experienced sales decline compared prior year included operational growth offset negative currency impact sales companies asiapacific africa region achieved growth compared prior year including operational growth partially offset negative currency impact company utilized three wholesalers distributing products three segments represented approximately total consolidated revenues company three wholesalers distributing products three segments represented approximately total consolidated revenues chartaccadacacjpganalysis sales business segments consumer segment consumer segment sales billion increase included operational growth negative currency impact us consumer segment sales billion increase international sales billion decrease included operational growth negative currency impact acquisitions divestitures net positive impact operational sales growth worldwide consumer segment major consumer franchise sales change dollars millions vs beauty otc baby care oral care womens health wound careother total consumer sales beauty franchise sales billion increased compared prior year growth primarily driven incremental sales acquisition ciz holdings co ltd drcilabo japan well market growth share gains neutrogena aveeno products growth partially offset divestitures roc nizoral fiscal year overthecounter otc franchise sales billion increased compared prior year growth primarily driven incremental sales acquisition zarbeesadditional contributors growthwere tylenol children 's motrin digestive health products antismoking aids baby care franchise sales billion decrease compared prior year primarily due johnsons competitive pressures coupled comparisons prior year relaunch activities baby center divestiture oral care franchise sales billion decreased compared prior year growth listerine mouthwash ready tabs outside us offset share declines retailer destocking us negative impact currency womens health franchise sales billion decrease compared prior year decline primarily driven negative impact currency weakness liners partially offset strength napkins asia pacific latin america wound careother franchise sales billion decrease compared prior year decline primarily driven divestiture compeed outside us negative impact currency pharmaceutical segment pharmaceutical segment sales billion increase included operational growth negative currency impact us sales billion increase international sales billion increase included operational growth negative currency impact net impact acquisitions divestitures pharmaceutical segment operational sales growth negligible adjustments previous reserve estimates compared prior year positively impacted pharmaceutical segment operational growth approximately primarily immunology cardiovascularmetabolismother therapeutic areas major pharmaceutical therapeutic area sales change vs dollars millions total immunology remicade simponisimponi aria stelara tremfya immunology total infectious diseases edurantrilpivirine prezista prezcobixrezolstasymtuza infectious diseases total neuroscience concertamethylphenidate invega sustennaxeplioninvega trinzatrevicta risperdal consta neuroscience total oncology darzalex imbruvica velcade zytiga abiraterone acetate oncology total pulmonary hypertension opsumit tracleer bosentan uptravi pulmonary hypertension total cardiovascular metabolism xarelto invokana invokamet procriteprex total pharmaceutical sales immunology products sales billion representing increase compared prior year growth driven strong uptake stelara ustekinumab crohn 's disease tremfya guselkumab psoriasis expanded indications simponisimponi aria golimumab us immunology market growth immunology negatively impacted lower sales remicade infliximab due increased discountsrebates biosimilar competition patents remicade infliximabin certain countries europe expired february biosimilar versions remicade introduced certain markets outside us resulting reduction sales remicade markets additional biosimilar competition likely result reduction remicade sales markets outside united states us biosimilar version remicade introduced additional competitors continue enter market continued infliximab biosimilar competition us market result reduction us sales remicade see note consolidated financial statements description legal matters regarding remicade patents infectious disease products sales billion representing increase compared prior year strong sales symtuza andthe launch juluca dolutegravirrilpivirine partially offset lower sales prezista prezcobixrezolsta darunavircobicistat due increased competition loss exclusivity prezista certain countries outside us neuroscience products sales billion representing increase compared prior year strong sales longacting injectables invega trinzatrevictapaliperidone palmitate invega sustennaxeplion partially offset cannibalization risperdal consta risperidone oncology products achieved sales billion representing increase compared prior year contributors growth strong sales darzalex daratumumab continued market growth share gain imbruvica ibrutinib due increased patient uptake globally additionally sales launch erleada apalutamide contributed growth growth negatively impacted decline us sales zytiga abiraterone acetate driven generic competition partially offset increased sales outside us lower sales velcade bortezomib also due generic competition pulmonary hypertension products achieved sales billion representing increase compared prior year sales opsumit macitentan uptravi selexipag due continued market growth increased share gains sales tracleer bosentan negatively impacted generics cannibalization opsumit cardiovascularmetabolismother products sales billion decline compared prior year xarelto rivaroxaban sales volume growth offset higher discounts rebates lower sales invokanainvokamet canagliflozin due share loss competitive pressure safety label update us lower sales procrit eprex epoetin alfa due biosimilar competition company advanced pipeline several regulatory submissions approvals new drugs additional indications existing drugs follows product name chemical us eu us eu name indication approval approval filing filing balversa erdafitinib treatment locally advanced metastatic urothelial cancer darzalex daratumumab combination regimen newly diagnosed transplanteligible patients multiple myeloma newly diagnosed patients multiple myeloma combination lenalidomide dexamethasone splitdosing regimen combination therapy transplant ineligible multiple myeloma patients subcutaneous formulation multiple myeloma erleada apalutamide treatment metastatic castrationsensitive prostate cancer treatment metastatic hormonesensitive prostate cancer expanded use combination obinutuzumab adult patients previously untreated chronic imbruvica ibrutinib lymphocytic leukemia combination rituximab waldenstrm 's macroglobulinemia treatment chronic lymphocytic leukemia combination obinutuzumab invokana canagliflozintreatment diabetic kidney disease rilpivirine cabotegravir monthly injectable two drug regimen treatment hiv spravato esketamine treatmentresistant depression rapid reduction depressive symptoms adults major depressive disorder active suicidal ideation intent stelara ustekinumab extended use treatment moderately severely active ulcerative colitis treatment pediatric patients moderate severe plaque psoriasis tremfya guselkumab onepress patientcontrolled injector treatment adults active psoriatic arthritis xarelto rivaroxaban prevention blood clots acutely ill medical patients medical devices segment medical devices segment sales billion decrease included operational decrease negative currency impact us sales billion decrease compared prior year international sales billion decrease compared prior year operational decrease negative currency impact net impact acquisitions divestitures medical devices segment worldwide operational sales growth negative divestitures lifescan advanced sterilization products asp impact approximately respectively major medical devices franchise sales change dollars millions vs surgery advanced general specialty orthopaedics hips knees trauma spine vision contact lensesother surgical interventional solutions diabetes care total medical devices sales lifescan divested fiscal fourth quarter percentage greater meaningful surgery franchise sales billion decrease growth advanced surgery primarily driven endocutter biosurgery energy products decline general surgery primarily driven negative impact currency partially offset growth wound closure products decline specialty surgery primarily driven divestiture sterilization business asp partially offset growth aesthetic products orthopaedics franchise sales billion decrease including operational growth offset negative currency impact compared prior year growth hips driven leadership position anterior approach strong market demand actis stem kincise surgical automated system knees grew outside us new products coupled continued global uptake attune revision offset negative currency impact growth trauma due strong market growth coupled continued uptake new products decline spine primarily driven base business declines spine partially offset growth sports led new products monovisc us growth asia pacific vision franchise achieved sales billion increase growth primarily driven strength daily disposable lenses acuvue oasys contact lenses category surgical operational growth primarily driven strength cataracts outside us partially offset competitive pressures us interventional solutions franchise achieved sales billion increase strong growth electrophysiology business driven atrial fibrillation procedure growth strong thermocool smarttouch sf contact force sensing catheter diagnostic catheter salesanalysis consolidated earnings provision taxes income consolidated earnings provision taxes income billion billion fiscal years ended respectively percent sales consolidated earnings provision taxes income respectively cost products sold selling marketing administrative expenses cost products sold selling marketing administrative expenses percent sales follows sales cost products sold percent point increasedecrease prior year selling marketing administrative expenses percent point increasedecrease prior year cost products sold percent sales increased compared period year ago primarily driven negative impact currency pharmaceutical business well increased intangible asset amortization expense intangible asset amortization expense billion included cost products sold compared billion decrease percent sales selling marketing administrative expenses compared prior year primarily due favorable segment mix higher percentage sales coming pharmaceutical business planned prioritization reduced brand marketing expense consumer business partially offset increased selling marketing investments medical devices business research development expense research development expense segment business follows dollars millions amount sales amount sales consumer pharmaceutical medical devices total research development expense percent increasedecrease prior year percent segment sales research development activities represent significant part company 's business expenditures relate processes discovering testing developing new products upfront payments developmental milestones improving existing products well ensuring product efficacy regulatory compliance prior launch company remains committed investing research development aim delivering high quality innovative products worldwide costs research development activities increased compared primarily driven increased investment medical devices business related robotics digital surgery platforms along higher upfront developmental milestone payments primarily argenx collaboration pharmaceutical business research facilities located us belgium brazil china france germany india israel netherlands poland singapore sweden switzerland united kingdom additional rd support countries inprocess research development iprd fiscal first quarter company recorded iprd charge billion remaining intangible asset value related development program al investigational drug treatment respiratory syncytial virus rsv human metapneumovirus hmpv acquired acquisition alios biopharma inc impairment charge based additional information including clinical data became available led company 's decision abandon development al fiscal third quarter company recorded impairment charge billion included partial impairment charge billion related development program al impairment charge billion discontinuation development project antithrombin antibody associated acquisition xo limited income expense net income expense net account company records gains losses related sale writedown certain investments equity securities held johnson johnson innovation jjdc inc jjdc unrealized gains losses investments gains losses divestitures certain transactional currency gains losses acquisitionrelated costs litigation accruals settlements well royalty income change income expense net fiscal year additional net expense billion primarily attributable litigation expense billion primarily related agreement principle settle opioid litigation billion compared litigation expense billion partially offset divestiture gains billion billion related divestiture asp business addition fiscal year included higher unrealized gains securities billion equity stepup gain billion related company 's previously held equity investment dr cilabo lower restructuring related expense billion compared period year ago divestiture gains approximately billion included lifescan business nizoral roc certain nonstrategic pharmaceutical products additionally included reversal contingent liability billion interest income expense fiscal year included net interest income compared expense fiscal year primarily due positive effect net investment hedging arrangements certain cross currency swaps lower average debt balance cash cash equivalents marketable securities totaled billion end averaged billion compared cash cash equivalents marketable securities total billion billion average cash balance total debt balance end billion average debt balance billion compared billion end average debt balance billion decrease debt due retirement longterm debt income tax segment income tax segment business follows income tax segment sales percent segment sales dollars millions consumer pharmaceutical medical devices total less net expense allocated segments earnings provision taxes income see note consolidated financial statements details amounts allocated segments include interest income expense general corporate income expense consumer segment consumer segment income tax percent sales versus decrease income tax percent sales compared primarily attributable higher expenses litigation billion intangible asset amortization billion restructuring billion fiscal year compared fiscal year partially offset planned prioritization brand marketing expense reductions fiscal year included gain billion related company 's previously held equity investment dr cilabo divestiture gains fiscal year included gain billion divestiture nizoral pharmaceutical segment pharmaceutical segment income tax percent sales versus decrease income tax percent sales primarily due higher litigation expense billion primarily due agreement principle settle opioid litigation billion increased spending research development including billion upfront payment argenx partially offset billion higher unrealized gains securities lower inprocess research development charge billion lower actelion acquisition integration related costs compared fiscal year addition fiscal year included contingent liability reversal billion higher divestiture gains billion medical devices segment medical devices segment income tax percent sales versus increase income tax percent sales primarily attributable higher divestiture gains divestiture gains fiscal included gain billion related asp business divestiture gains fiscal year included gain billion related lifescan additionally fiscal year included lower litigation expense billion lower restructuring charges billion lower intangible asset amortization expense billion compared fiscal year partially offset increased investment robotics digital solutions restructuring fiscal second quarter company announced plans implement actions across global supply chain intended enable company focus resources increase investments critical capabilities technologies solutions necessary manufacture supply product portfolio future enhance agility drive growth company expects supply chain actions include expanding use strategic collaborations bolstering initiatives reduce complexity improving costcompetitiveness enhancing capabilities optimizing network discussions regarding specific future actions ongoing subject relevant consultation requirements finalized total company expects actions generate approximately billion annual pretax cost savings substantially delivered company expects record pretax restructuring charges approximately billion company estimates approximately cumulative pretax costs result cash outlays company recorded pretax charge billion included following lines consolidated statement earnings billion restructuring billion income expense billion cost products sold total project costs approximately billion recorded since restructuring announced see note consolidated financial statements additional details related restructuring programs provision taxes income worldwide effective income tax rate discussion related fiscal provision taxes refer note consolidated financial statements september swiss parliament approved federal act tax reform ahv financing traf may public referendum held switzerland approved federal reform proposals fiscal third quarter swiss federal council enacted traf became effective january february public referendum legislative change held last remaining canton company significant operations legislation approved voters formal enactment expected fiscal first half company yet elected transitional provision canton however net financial benefit estimated billion billion fiscal first half company believe traf material impact companys ongoing consolidated effective tax rate beginning fiscal year liquidity capital resources liquidity cash flows cash cash equivalents billion end compared billion end primary sources uses cash contributed billion decrease approximately billion cash generated operating activities offset billion net cash used investing activities billion net cash used financing activities addition company billion marketable securities end billion end see note consolidated financial statements additional details cash cash equivalents marketable securities cash flow operations billion result billion net earnings billion noncash expenses adjustments depreciation amortization stockbased compensation assets writedowns primarily related alios iprd asset favorable increases accounts payable accrued liabilities liabilities billion reduced billion related increase accounts receivable inventories current noncurrent assets well noncash expenses adjustments billion increase deferred tax provision net gain sale assetsbusinesses billion primarily related asp divestiture investing activities use billion cash primarily used acquisitions billion primarily related acquisitions auris health inc dr cilabo additions property plant equipment billion billion net purchases investments investing activities also included source billion proceeds disposal assetsbusinesses primarily asp divestiture proceeds credit support agreements billion financing activities use billion cash primarily used dividends shareholders billion repurchase common stock billion net retirement short long term debt billion financing activities also included sources billion proceeds stock options exercisedemployee withholding tax stock awards financing activities december company announced board directors approved share repurchase program authorizing company purchase billion company 's shares common stock shares acquired available general corporate purposes company financed share repurchase program available cash september billion repurchased program program completed december company 's notes payable longterm debt excess cash cash equivalents marketable securities december net debt position billion compared prior year billion decrease net debt position due retirement debt debt balance end billion compared billion company continued access liquidity commercial paper market additionally result tcja company access cash outside us significantly reduced cost company anticipates operating cash flows ability raise funds external sources borrowing capacity existing committed credit facilities access commercial paper markets continue provide sufficient resources fund operating needs including agreement principle settle opioid litigation potentially paid next two three years discussed note consolidated financial statements internal revenue service irs completed audit tax years currently auditing tax years company currently expects completion audit settlement related tax liabilities fiscal year december company classified unrecognized tax benefits related interest approximately billion current liability accrued taxes income line consolidated balance sheet amount expected paid next months respect irs audit subsequent december company made payment approximately billion us treasury related estimated tax audit liability anticipation final settlement later fiscal completion tax audit may result additional adjustments companys unrecognized tax benefit liability may material impact companys future operating results cash flows period audit substantially completed company monitors global capital markets ongoing basis time time may raise capital market conditions favorable company filed shelf registration february enable issue debt securities timely basis updated required additional details borrowings see note consolidated financial statements financing market risk company uses financial instruments manage impact foreign exchange rate changes cash flows accordingly company enters forward foreign exchange contracts protect value certain foreign currency assets liabilities hedge future foreign currency transactions primarily related product costs gains losses contracts offsetby gains losses underlying transactions appreciation us dollar december market rates would increase unrealized value companys forward contracts million conversely depreciation us dollar december market rates would decrease unrealized value companys forward contracts million either scenario gain loss forward contract would offset gain loss underlying transaction therefore would impact future anticipated earnings cash flows company hedges exposure fluctuations currency exchange rates effect certain assets liabilities foreign currency entering currency swap contracts change spread us foreign interest rates companys interest rate sensitive financial instruments would either increase decrease unrealized value companys swap contracts approximately million either scenario maturity gain loss swap contract would offset gain loss underlying transaction therefore would impact future anticipated cash flows company enter financial instruments trading speculative purposes company policy entering contracts parties least investment grade credit rating counterparties contracts major financial institutions significant concentration exposure one counterparty management believes risk loss remote fiscal second quarter company entered credit support agreements csa certain derivative counterparties establishing collateral thresholds based respective credit ratings netting agreements see note consolidated financial statements additional details credit support agreements company invests fixed rate floating rate interest earning securities carry degree interest rate risk fair market value fixed rate securities may adversely impacted due rise interest rates floating rate securities may produce less income predicted interest rates fall basis points change spread companys interest rate sensitive investments would either increase decrease unrealized value cash equivalents current marketable securities approximately million company access substantial sources funds numerous banks worldwide september company secured new day credit facility total credit available company approximates billion expires september interest charged borrowings credit line agreement based either bids provided banks prime rate london interbank offered rates libor applicable market rate allowed terms agreement plus applicable margins commitment fees agreement material total borrowings end billion billion respectively decrease borrowings due retirement debt net debt cash current marketable securities net debt billion compared net debt billion total debt represented total capital shareholders equity total debt total capital shareholders equity per share end compared yearend summary borrowings found note consolidated financial statements contractual obligations commitments companys contractual obligations primarily recently enacted tax legislation leases debt unfunded retirement plans significant obligations satisfy obligations company use cash operations following table summarizes companys contractual obligations aggregate maturities december see notes consolidated financial statements details interest unfunded tax legislation debt debt retirement dollars millions tcja obligations obligations plans leases total total tax matters see note consolidated financial statements retirement plan postemployment medical benefit information see note consolidated financial statements table include activity related business combinationsdividends company increased dividend th consecutive year cash dividends paid per share per share information critical accounting policies estimates managements discussion analysis results operations financial condition based companys consolidated financial statements prepared accordance accounting principles generally accepted us gaap preparation financial statements requires management make estimates assumptions affect amounts reported revenues expenses assets liabilities related disclosures actual results may may differ estimates company believes understanding certain key accounting policies estimates essential achieving insight companys operating results financial condition key accounting policies include revenue recognition income taxes legal selfinsurance contingencies valuation longlived assets assumptions used determine amounts recorded pensions employee benefit plans accounting stock based awards revenue recognition company recognizes revenue product sales obligations terms contract customer satisfied generally occurs transfer control goods customers company 's global payment terms typically days provisions certain rebates sales incentives trade promotions coupons product returns discounts customers accounted variable consideration recorded reduction sales see note consolidated financial statements accounting standards update related revenue adopted product discounts granted based terms arrangements direct indirect market participants well market conditions including consideration competitor pricing rebates estimated based contractual terms historical experience patient outcomes trend analysis projected market conditions various markets served company evaluates market conditions products groups products primarily analysis wholesaler thirdparty sellthrough market research data well internally generated information sales returns estimated recorded based historical sales returns information products exhibit unusual sales return patterns due dating competition marketing matters specifically investigated analyzed part accounting sales return accruals sales returns allowances represent reserve products may returned due expiration destruction field specific areas product recall sales returns reserve based historical return trends product market percent gross sales accordance companys accounting policies company generally issues credit customers returned goods companys sales returns reserves accounted accordance us gaap guidance revenue recognition right return exists sales returns reserves recorded full sales value sales returns consumer pharmaceutical segments almost exclusively resalable sales returns certain franchises medical devices segment typically resalable material company infrequently exchanges products inventory returned products sales returns reserve total company approximately annual net trade sales fiscal reporting years promotional programs product listing allowances cooperative advertising arrangements recorded period related sales continuing promotional programs include coupons volumebased sales incentive programs redemption cost consumer coupons based historical redemption experience product value volumebased incentive programs based estimated sales volumes incentive period recorded products sold arrangements evaluated determine appropriate amounts deferred recorded reduction revenue company also earns profitshare payments collaborative arrangements certain products included sales customers years presented profitshare payments approximately total revenues included sales customers addition company enters collaboration arrangements contain multiple revenue generating activities amounts due collaborative partners arrangements recognized activity performed delivered based relative selling price upfront fees received part arrangements deferred recognized performance period see note consolidated financial statements additional disclosures collaborations reasonably likely changes assumptions used calculate accruals rebates returns promotions anticipated material effect financial statements company currently discloses impact changes assumptions quarterly annual filing material financial statement impactbelow tables show progression accrued rebates returns promotions reserve doubtful accounts reserve cash discounts segment business fiscal years ended december december consumer segment balance beginning balance dollars millions period accruals paymentscredits end period accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total includes reserve customer rebates million december million december recorded contra asset pharmaceutical segment balance beginning balance dollars millions period accruals paymentscredits end period accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total includes reserve customer rebates million december million december recorded contra asset includes adjustments medical devices segment balance beginning balance dollars millions period accruals paymentscredits end period accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total includes reserve customer rebates million december million december recorded contra asset certain prior period amounts reclassified conform current year presentation income taxes income taxes recorded based amounts refundable payable current year include results difference us gaap accounting tax reporting recorded deferred tax assets liabilities company estimates deferred tax assets liabilities based enacted tax regulations rates future changes tax laws rates may affect recorded deferred tax assets liabilities company unrecognized tax benefits uncertain tax positions company follows us gaap prescribes recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return management believes changes estimates would material effect company 's results operations cash flows financial position company recorded deferred tax liabilities undistributed earnings prior december international subsidiaries company provided deferred taxes undistributed earnings subsequent january certain international subsidiaries earnings considered indefinitely reinvested company intends continue reinvest earnings international operations company decides later date repatriate earnings us company would required provide net tax effects amounts company estimates total tax effect repatriation would approximately billion current enacted tax laws regulations current currency exchange rates see note consolidated financial statements information regarding income taxes legal self insurance contingencies company records accruals various contingencies including legal proceedings product liability claims arise normal course business accruals based managements judgment probability losses applicable actuarially determined estimates company self insurance whollyowned captive insurance company addition accruals self insurance programclaims exceed insurance coverage accrued losses probable amounts reasonably estimated company follows provisions us gaap recording litigation related contingencies liability recorded loss probable reasonably estimated best estimate loss within range accrued however estimate range better minimum amount accrued see notes consolidated financial statements information regarding product liability legal proceedings longlived intangible assets company assesses changes economic conditions makes assumptions regarding estimated future cash flows evaluating value companys property plant equipment goodwill intangible assets assumptions estimates may change time may may necessary company record impairment charges employee benefit plans company sponsors various retirement pension plans including defined benefit defined contribution termination indemnity plans cover employees worldwide plans based assumptions discount rate expected return plan assets mortality rates expected salary increases health care cost trend rates attrition rates see note consolidated financial statements details rates effect rate change health care cost trend would companys results operations stock based compensation company recognizes compensation expense associated issuance equity instruments employees services based type equity instrument fair value estimated date grant using either blackscholes option valuation model combination blackscholes option valuation model monte carlo valuation model expensed financial statements service period input assumptions used determining fair value expected life expected volatility riskfree rate expected dividend yield performance share units fair market value calculated three component goals date grant fair values sales earnings per share goals performance share unit estimated date grant using fair market value shares time award discounted dividends paid performance share units vesting period fair value relative total shareholder return goal performance share unit estimated date grant using monte carlo valuation model see note consolidated financial statements additional information new accounting pronouncements refer note consolidated financial statements recently adopted accounting pronouncements recently issued accounting pronouncements yet adopted december economic market factors company aware products used environment decade policymakers consumers businesses expressed concerns rising cost health care response concerns company longstanding policy pricing products responsibly period us weighted average compound annual growth rate companys net price increases health care products prescription overthecounter drugs hospital professional products us consumer price index cpi company operates certain countries economic conditions continue present significant challenges company continues monitor situations take appropriate actions inflation rates continue effect worldwide economies consequently way companies operate company accounted operations argentina beginning fiscal third quarter venezuela highly inflationary prior threeyear cumulative inflation rate surpassed material impact company 's results period face increasing costs company strives maintain profit margins cost reduction programs productivity improvements periodic price increases june united kingdom uk held referendum voters approved exit european union eu commonly referred brexit january uk formally exited eu given lack comparable precedent unclear ultimate financial trade regulatory legal implications withdrawal uk eu brexit creates global political economic uncertainty may cause among consequences volatility exchange rates interest rates additional cost containment thirdparty payors changes regulations however company currently believe related effects material impact companys consolidated financial position operating results december business companys uk subsidiaries represented less companys consolidated assets fiscal twelve months revenues respectively company exposed fluctuations currency exchange rates change value us dollar compared foreign currencies company sales income expense would increased decreased translation foreign sales approximately million net income approximately million governments around world consider various proposals make changes tax laws may include increasing decreasing existing statutory tax rates change statutory tax rate country would result revaluation companys deferred tax assets liabilities related particular jurisdiction period new tax law isenacted change would result expense benefit recorded companys consolidated statement earnings company closely monitors proposals arise countries operates changes statutory tax rate may occur time related expense benefit recorded may material fiscal quarter year law change enacted discussion federal act tax reform ahv financing swiss tax reform see provision taxes income management 's discussion analysis financial condition results operations company faces various worldwide health care changes may continue result pricing pressures include health care cost containment government legislation relating sales promotions reimbursement health care products changes behavior spending patterns purchasers health care products services including delaying medical procedures rationing prescription medications reducing frequency physician visits foregoing health care insurance coverage result current global economic downturn may continue impact companys businesses company also operates environment increasingly hostile intellectual property rights firms filed abbreviated new drug applications biosimilar biological product applications fda otherwise challenged coverage andor validity company 's patents seeking market generic biosimilar forms many companys key pharmaceutical products prior expiration applicable patents covering products event company successful defending patent claims challenged resulting lawsuits generic biosimilar versions products issue introduced market resulting potential substantial market share revenue losses products may result noncash impairment charge associated intangible asset also risk one competitors could launch generic biosimilar version product issue following regulatory approval even though one valid patents place information see discussion remicade related cases litigation filers abbreviated new drug applications note consolidated financial statements legal proceedings johnson johnson certain subsidiaries involved various lawsuits claims regarding product liability intellectual property commercial matters governmental investigations legal proceedings arise time time ordinary course business company records accruals loss contingencies associated legal matters probable liability incurred amount loss reasonably estimated december company determined liabilities associated certain litigation matters probable reasonably estimated company accrued matters continue monitor related legal issue adjust accruals might warranted based new information developments accordance asc litigation regulatory matters discussed loss probable reasonably possible company unable estimate possible loss range loss beyond amounts already accrued amounts accrued legal contingencies often result complex series judgments future events uncertainties rely heavily estimates assumptions including timing related payments ability make estimates judgments affected various factors including among things whether damages sought proceedings unsubstantiated indeterminate scientific legal discovery commenced complete proceedings early stages matters present legal uncertainties significant facts dispute procedural jurisdictional issues uncertainty unpredictability number potential claims numerous parties involved extent adverse verdicts rendered company company record accrual loss determined probable reasonably estimated company 's opinion based examination matters experience date discussions counsel ultimate outcome legal proceedings net liabilities accrued company 's balance sheet expected material adverse effect company 's financial position however resolution increase accruals one matters reporting period may material adverse effect company 's results operations cash flows period see note consolidated financial statements information regarding legal proceedings common stock companys common stock listed new york stock exchange symbol jnj february record holders common stock company item quantitative qualitative disclosures market risk information called item incorporated herein reference item managements discussion analysis results operations financial condition liquidity capital resources financing market risk report note summary significant accounting policies financial instruments notes consolidated financial statements included item reportitem financial statements supplementary data index audited consolidated financial statements consolidated balance sheets consolidated statements earnings consolidated statements comprehensive income consolidated statements equity consolidated statements cash flows notes consolidated financial statements report independent registered public accounting firm managements report internal control financial reporting johnson johnson subsidiaries consolidated balance sheets december december dollars millions except share per share amounts note assets current assets cash cash equivalents notes marketable securities notes accounts receivable trade less allowances doubtful accounts inventories notes prepaid expenses receivables assets held sale note total current assets property plant equipment net notes intangible assets net notes goodwill notes deferred taxes income note assets total assets liabilities shareholders equity current liabilities loans notes payable note accounts payable accrued liabilities accrued rebates returns promotions accrued compensation employee related obligations accrued taxes income note total current liabilities longterm debt note deferred taxes income note employee related obligations notes longterm taxes payable note liabilities total liabilities commitments contingencies note shareholders equity preferred stock without par value authorized unissued shares common stock par value per share note authorized shares issued shares accumulated comprehensive income loss note retained earnings less common stock held treasury cost note shares shares total shareholders equity total liabilities shareholders equity see notes consolidated financial statements johnson johnson subsidiaries consolidated statements earnings dollars shares millions except per share amounts note sales customers cost products sold gross profit selling marketing administrative expenses research development expense inprocess research development note interest income interest expense net portion capitalized note income expense net restructuring note earnings provision taxes income provision taxes income note net earnings net earnings per share notes basic diluted average shares outstanding notes basic diluted see notes consolidated financial statements johnson johnson subsidiaries consolidated statements comprehensive income dollars millions note net earnings comprehensive income loss net tax foreign currency translation securities unrealized holding gain loss arising period reclassifications earnings net change employee benefit plans prior service credit cost net amortization gain loss net amortization effect exchange rates net change derivatives hedges unrealized gain loss arising period reclassifications earnings net change comprehensive income loss comprehensive income tax effects comprehensive income fiscal years ended respectively foreign currency translation million million securities million employee benefit plans million million million derivatives hedges million million million see notes consolidated financial statements johnson johnson subsidiaries consolidated statements equity dollars millions note accumulated common stock treasury retained comprehensive issued stock total earnings income loss amount amount balance january net earnings cash dividends paid per share employee compensation stock option plans repurchase common stock comprehensive income loss net tax balance december cumulative adjustment net earnings cash dividends paid per share employee compensation stock option plans repurchase common stock comprehensive income loss net tax balance december net earnings cash dividends paid per share employee compensation stock option plans repurchase common stock comprehensive income loss net tax balance december see note consolidated financial statements additional details effect cumulative adjustments retained earnings see notes consolidated financial statements johnson johnson subsidiaries consolidated statements cash flows dollars millions note cash flows operating activities net earnings adjustments reconcile net earnings cash flows operating activities depreciation amortization property intangibles stock based compensation asset writedowns gain sale assetsbusinesses deferred tax provision accounts receivable allowances changes assets liabilities net effects acquisitions divestitures increase accounts receivable increasedecrease inventories increase accounts payable accrued liabilities increase current noncurrent assets increasedecrease current noncurrent liabilities net cash flows operating activities cash flows investing activities additions property plant equipment proceeds disposal assetsbusinesses net acquisitions net cash acquired note purchases investments sales investments proceeds credit support agreements net cash used investing activities cash flows financing activities dividends shareholders repurchase common stock proceeds shortterm debt repayment shortterm debt proceeds longterm debt net issuance costs repayment longterm debt proceeds exercise stock optionsemployee withholding tax stock awards net net cash used financing activities effect exchange rate changes cash cash equivalents decreaseincrease cash cash equivalents cash cash equivalents beginning year note cash cash equivalents end year note supplemental cash flow data cash paid year interest interest net amount capitalized income taxes supplemental schedule noncash investing financing activities treasury stock issued employee compensation stock option plans net cash proceeds employee withholding tax stock awards conversion debt acquisitions fair value assets acquired fair value liabilities assumed noncontrolling interests net cash paid acquisitions note see notes consolidated financial statements notes consolidated financial statements summary significant accounting policies principles consolidation consolidated financial statements include accounts johnson johnson subsidiaries company intercompany accounts transactions eliminated columns rows within tables may add due rounding percentages calculated using actual nonrounded figures description company business segments company approximately employees worldwide engaged research development manufacture sale broad range products health care field company conducts business virtually countries world primary focus products related human health wellbeing company organized three business segments consumer pharmaceutical medical devices consumer segment includes broad range products used baby care oral care beauty overthecounter pharmaceutical womens health wound care markets products marketed general public sold retail outlets distributors throughout world pharmaceutical segment focused six therapeutic areas including immunology infectious diseases neuroscience oncology pulmonary hypertension cardiovascular metabolic diseases products segment distributed directly retailers wholesalers hospitals health care professionals prescription use medical devices segment includes broad range products used orthopaedic surgery interventional solutions cardiovascular neurovascular eye health fields distributed wholesalers hospitals retailers used principally professional fields physicians nurses hospitals eye care professionals clinics new accounting standards recently adopted accounting standards asu leases company adopted standard beginning fiscal year prospective basis update requires recognition lease assets lease liabilities balance sheet lease obligations disclosing key information leasing arrangements update requires recognition lease assets lease liabilities lessees arrangements classified operating leases companys operating leases resulted recognition additional assets corresponding liabilities consolidated balance sheet however material impact consolidated financial statements company determines whether arrangement lease contract inception establishing contract conveys right control use identified property plant equipment period time exchange consideration right use rou assets lease liabilities operating leases included assets accrued liabilities liabilities consolidated balance sheet rou assets represent right use underlying asset lease term lease liabilities represent obligation make lease payments arising lease commitments finance leases significant included property plant equipment loans notes payable longterm debt consolidated balance sheet rou assets lease liabilities recognized lease commencement date based present value minimum lease payments lease term company uses incremental borrowing rate based information available commencement date determining present value lease payments implicit rate readily determinable lease terms may include options extend terminate lease options included lease term reasonably certain company exercise option operating lease expense recognized straightline basis lease term company elected following policy elections adoption use portfolio approach leases assets master service agreements exclusion short term leases balance sheet separating lease nonlease components additional disclosures see note consolidated financial statements asu reclassification certain tax effects accumulated comprehensive income update allows company elect reclassify stranded tax effects resulting tax cuts job act enacted december accumulated comprehensive income retained earnings company elected reclassifythe income tax effects standard therefore standard impact company 's consolidated financial statements asu derivatives hedging topic asc update adds overnight index swap ois rate based secured overnight financing rate sofr eligible benchmark interest rate permitted application hedge accounting guidance effective company fiscal fourth quarter due previous adoption asu impact adoption guidance material impact companys consolidated financial statements related disclosures standard may impact future market sofr derivatives develops time sofr used hedge companys financial instruments accounting standards adopted fiscal cumulative effect opening balance retained earnings following table summarizes cumulative effect adjustments made opening balance retained earnings upon adoption new accounting standards mentioned cumulative effect adjustment increase decrease retained dollars millions earnings asu revenue contracts customers asu financial instruments asu income taxes intraentity transfers total recently issued accounting standards adopted december asu collaborative arrangements update clarifies interaction asc collaborative arrangements asc revenue contracts customers update clarifies certain transactions participants collaborative arrangement accounted asc counterparty customer addition update precludes entity presenting consideration transaction collaborative arrangement revenue counterparty customer transaction update effective company fiscal years beginning december interim periods within fiscal years asu applied retrospectively date initial application asc early adoption permitted adoption standard material impact companys consolidated financial statements asu financial instruments credit losses update introduces current expected credit loss cecl model require entity measure credit losses certain financial instruments financial assets including trade receivables update initial recognition reporting period entity required recognize allowance reflects entitys current estimate credit losses expected incurred life financial instrument update effective company fiscal years beginning december interim periods within fiscal years early adoption permitted adoption standard material impact companys consolidated financial statements cash equivalents company classifies highly liquid investments stated maturities three months less date purchase cash equivalents highly liquid investments stated maturities greater three months date purchase current marketable securities company policy making investments commercial institutions least investment grade credit rating company invests cash primarily government securities obligations corporate debt securities money market funds reverse repurchase agreements rras rras collateralized deposits form government securities obligations amount less value company record asset liability company permitted sell repledge associated collateral company policy collateral least equivalent credit rating company utilizes third party custodian manage exchange funds ensure collateral received maintained value rras daily basis rras stated maturities greater three months date purchase classified marketable securitiesinvestments investments classified held maturity investments reported amortized cost realized gains losses reported earnings investments classified availableforsale debt securities carried estimated fair value unrealized gains losses recorded component accumulated comprehensive income availableforsale securities available current operations classified current assets otherwise classified long term management determines appropriate classification investment debt equity securities time purchase reevaluates determination balance sheet date company reviews investments impairment adjusts investments fair value earnings required property plant equipment depreciation property plant equipment stated cost company utilizes straightline method depreciation estimated useful lives assets building building equipment years land leasehold improvements years machinery equipment years company capitalizes certain computer software development costs included machinery equipment incurred connection developing obtaining computer software internal use capitalized software costs amortized estimated useful lives software generally range years company reviews longlived assets assess recoverability using undiscounted cash flows certain events changes operating economic conditions occur impairment assessment may performed recoverability carrying value assets asset determined impaired loss measured based difference assets fair value carrying value quoted market prices available company estimate fair value using discounted value estimated future cash flows revenue recognition company recognizes revenue product sales obligations terms contract customer satisfied generally occurs transfer control goods customers company 's global payment terms typically days provisions certain rebates sales incentives trade promotions coupons product returns discounts customers accounted variable consideration recorded reduction sales liability recognized within accrued rebates returns promotions consolidated balance sheet product discounts granted based terms arrangements direct indirect market participants well market conditions including consideration competitor pricing rebates estimated based contractual terms historical experience patient outcomes trend analysis projected market conditions various markets served significant portion liability related rebates sale company 's pharmaceutical products within us primarily managed care medicare medicaid programs amounted billion billion december december respectively company evaluates market conditions products groups products primarily analysis wholesaler thirdparty sellthrough market research data well internally generated information sales returns estimated recorded based historical sales returns information products exhibit unusual sales return patterns due dating competition marketing matters specifically investigated analyzed part accounting sales return accruals sales returns allowances represent reserve products may returned due expiration destruction field specific areas product recall sales returns reserve based historical return trends product market percent gross sales accordance companys accounting policies company generally issues credit customers returned goods companys sales returns reserves accounted accordance us gaap guidance revenue recognition right return exists sales returns reserves recorded full sales value sales returns consumer pharmaceutical segments almost exclusively resalable sales returns certain franchises medical devices segment typically resalable material company infrequently exchanges products inventory returned products sales returns reserve total company approximately annual net trade sales fiscal reporting years promotional programs product listing allowances cooperative advertising arrangements recorded thesame period related sales continuing promotional programs include coupons volumebased sales incentive programs redemption cost consumer coupons based historical redemption experience product value volumebased incentive programs based estimated sales volumes incentive period recorded products sold arrangements evaluated determine appropriate amounts deferred recorded reduction revenue company also earns profitshare payments collaborative arrangements certain products included sales customers years presented profitshare payments approximately total revenues included sales customers see note consolidated financial statements disaggregation revenue shipping handling shipping handling costs incurred billion billion billion respectively included selling marketing administrative expense amount revenue received shipping handling less sales customers periods presented inventories inventories stated lower cost net realizable value determined firstin firstout method intangible assets goodwill authoritative literature us gaap requires goodwill intangible assets indefinite lives assessed annually impairment company completed annual impairment test fiscal fourth quarter future impairment tests performed annually fiscal fourth quarter sooner warranted purchased inprocess research development accounted indefinite lived intangible asset underlying project completed point intangible asset accounted definite lived intangible asset abandoned point intangible asset written partially impaired intangible assets finite useful lives continue amortized useful lives reviewed impairment warranted economic conditions see note details intangible assets goodwill financial instruments required us gaap derivative instruments recorded balance sheet fair value fair value exit price would received sell asset paid transfer liability fair value marketbased measurement determined using assumptions market participants would use pricing asset liability authoritative literature establishes threelevel hierarchy prioritize inputs used measuring fair value level highest priority level lowest changes fair value derivatives recorded period current earnings comprehensive income depending whether derivative designated part hedge transaction type hedge transaction company documents relationships hedged items derivatives overall risk management strategy includes reasons undertaking hedge transactions entering derivatives objectives strategy minimize foreign currency exposures impact companys financial performance protect companys cash flow adverse movements foreign exchange rates ensure appropriateness financial instruments manage enterprise risk associated financial institutions see note additional information financial instruments product liability accruals product liability claims recorded undiscounted basis probable liability incurred amount liability reasonably estimated based existing information actuarially determined estimates applicable accruals adjusted periodically additional information becomes available company accrues estimate legal defense costs needed defend matter costs probable reasonably estimated extent adverse verdicts rendered company company record accrual loss determined probable reasonably estimated company self insurance whollyowned captive insurance company addition accruals self insurance program claims exceed insurance coverage accrued losses probable amounts reasonably estimated research development research development expenses expensed incurred accordance asc research development upfront milestone payments made third parties connection research development collaborations expensed incurred point regulatory approval payments made third parties subsequent regulatory approval capitalized amortized remaining useful life related product amounts capitalized payments included intangibles net accumulated amortization company enters collaborative arrangements typically pharmaceutical biotechnology companies develop commercialize drug candidates intellectual property arrangements typically involve two parties active participants collaboration exposed significant risks rewards dependent commercial success activities collaborations usually involve various activities one parties including research anddevelopment marketing selling distribution often collaborations require upfront milestone royalty profit share payments contingent upon occurrence certain future events linked success asset development amounts due collaborative partners related development activities generally reflected reduction research development expense performance contract development services central companys operations general income statement presentation collaborations follows naturetype collaboration statement earnings presentation thirdparty sale product profit share payments received sales customers royaltiesmilestones paid collaborative partner post cost products sold regulatory approval royalties received collaborative partner income expense net upfront payments milestones paid collaborative partner research development expense preregulatory approval research development payments collaborative partner research development expense research development payments received reduction research development expense collaborative partner milestones capitalized intangible assets amortized cost products sold useful life years presented individual project represented greater total annual consolidated research development expense company number products compounds developed collaboration strategic partners including xarelto codeveloped bayer healthcare ag imbruvica developed collaboration comarketed pharmacyclics llc abbvie company separately company number licensing arrangements products compounds including darzalex licensed genmab advertising costs associated advertising expensed year incurred included selling marketing administrative expenses advertising expenses worldwide comprised television radio print media internet advertising billion billion billion respectively income taxes income taxes recorded based amounts refundable payable current year include results difference us gaap accounting tax reporting recorded deferred tax assets liabilities company estimates deferred tax assets liabilities based enacted tax regulations rates future changes tax laws rates may affect recorded deferred tax assets liabilities future company unrecognized tax benefits uncertain tax positions company follows us gaap prescribes recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return management believes changes estimates would material effect company 's results operations cash flows financial position january fasb issued guidance allows companies elect accounting policy whether record tax effects global intangible lowtaxed income gilti period tax liability generated ie period cost provide deferred tax assets liabilities related basis differences exist expected effect amount gilti inclusion future years upon reversal ie deferred method fiscal company elected account gilti deferred method deferred tax amounts recorded based evaluation temporary differences expected reverse gilti incurred future periods company recorded deferred tax liabilities undistributed earnings prior december international subsidiaries company provided deferred taxes undistributed earnings subsequent january certain international subsidiaries earnings considered indefinitely reinvested company intends continue reinvest earnings international operations company decides later date repatriate earnings us company would required provide net tax effects amounts company estimates total tax effect repatriation would approximately billion current enacted tax laws regulations current currency exchange rates see note consolidated financial statementsfor information regarding income taxesnet earnings per share basic earnings per share computed dividing net earnings available common shareholders weighted average number common shares outstanding period diluted earnings per share reflects potential dilution could occur securities exercised converted common stock using treasury stock method use estimates preparation consolidated financial statements conformity accounting principles generally accepted us requires management make estimates assumptions affect amounts reported estimates used accounting sales discounts rebates allowances incentives product liabilities income taxes withholding taxes depreciation amortization employee benefits contingencies intangible asset liability valuations actual results may may differ estimates company follows provisions us gaap recording litigation related contingencies liability recorded loss probable reasonably estimated best estimate loss within range accrued however estimate range better minimum amount accrued annual closing date company follows concept fiscal year ends sunday nearest end month december normally fiscal year consists weeks every five six years fiscal year consists weeks therefore includes additional shipping days case case reclassification certain prior period amounts reclassified conform current year presentation cash cash equivalents current marketable securities end fiscal year cash cash equivalents current marketable securities comprised dollars millions current carrying cash cash marketable amount equivalents securities cash nonus sovereign securities us reverse repurchase agreements reverse repurchase agreements corporate debt securities money market funds time deposits subtotal us gov't securities corporate debt securities subtotal available sale total cash cash equivalents current marketable securities dollars millions current carrying cash cash marketable amount equivalents securities cash us reverse repurchase agreements reverse repurchase agreements money market funds time deposits subtotal gov't securities corporate debt securities subtotal available sale total cash cash equivalents current marketable securities held maturity investments reported amortized cost realized gains losses reported earnings available sale debt securities reported fair value unrealized gains losses reported net taxes comprehensive income fair value government securities obligations corporate debt securities estimated using quoted broker prices significant observable inputs carrying amount estimated fair value contractual maturities available sale debt securities december follows cost basis fair value dollars millions due within one year due one year five years due five years ten years total debt securities company invests excess cash deposits major banks throughout world highquality money market instruments company policy making investments commercial institutions least investment grade credit rating inventories end inventories comprised dollars millions raw materials supplies goods process finished goods total inventories see note consolidated financial statements details assets held sale related divestitures property plant equipment end property plant equipment cost accumulated depreciation dollars millions land land improvements buildings building equipment machinery equipment construction progress total property plant equipment gross less accumulated depreciation total property plant equipment net see note consolidated financial statements details assets held sale related divestitures company capitalizes interest expense part cost construction facilities equipment interest expense capitalized million million million respectively depreciation expense including amortization capitalized interest billion billion billion respectively upon retirement disposal property plant equipment costs related amounts accumulated depreciation amortization eliminated asset accumulated depreciation accounts respectively difference net asset value proceeds recorded earnings intangible assets goodwill end gross net amounts intangible assets dollars millions intangible assets definite lives patents trademarks gross less accumulated amortization patents trademarks net customer relationships intangibles gross less accumulated amortization customer relationships intangibles net intangible assets indefinite lives trademarks purchased inprocess research development total intangible assets indefinite lives total intangible assets net majority comprised customer relationships fiscal year company completed acquisition auris health inc recorded inprocess research development intangible asset billion additionally fiscal first quarter company recorded iprd impairment charge billion remaining intangible asset value related development program al investigational drug treatment respiratory syncytial virus rsv human metapneumovirus hmpv acquired acquisition alios biopharma inc impairment charge based additional information including clinical data became available led company 's decision abandon development al partial impairment charge billion previously recorded fiscal third quarter related development program algoodwill december december allocated segment business follows dollars millions consumer pharmaceutical medical devices total goodwill december goodwill related acquisitions goodwill related divestitures currency translationother goodwill december goodwill related acquisitions currency translationother goodwill december goodwill billion related divestiture lifescan business goodwill billion related divestiture advanced sterilization products business closed pending classified assets held sale consolidated balance sheet december weighted average amortization period patents trademarks years weighted average amortization period customer relationships intangible assets years amortization expense amortizable assets included cost products sold billion billion billion tax fiscal years ended december december december respectively intangible asset writedowns included income expense net estimated amortization expense approved products tax five succeeding years approximately dollars millions see note consolidated financial statements additional details related acquisitions divestitures fair value measurements company uses forward foreign exchange contracts manage exposure variability cash flows primarily related foreign exchange rate changes future intercompany products thirdparty purchases materials denominated foreign currency company uses cross currency interest rate swaps manage currency risk primarily related borrowings types derivatives designated cash flow hedges additionally company uses interest rate swaps instrument manage interest rate risk related fixed rate borrowings derivatives designated fair value hedges company uses cross currency interest rate swaps forward foreign exchange contracts designated net investment hedges additionally company uses forward foreign exchange contracts offset exposure certain foreign currency assets liabilities forward foreign exchange contracts designated hedges therefore changes fair values derivatives recognized earnings thereby offsetting current earnings effect related foreign currency assets liabilities company enter derivative financial instruments trading speculative purposes contain credit risk related contingent features company maintains credit support agreements csa certain derivative counterparties establishing collateral thresholds based respective credit ratings netting agreements december total amount cash collateral held company credit support agreements csa amounted million net primarily related net investment hedges ongoing basis company monitors counterparty credit ratings company considers credit nonperformance risk low company primarily enters agreements commercial institutions least investment grade credit rating refer table significant financial assets andliabilities measured fair value contained footnote receivables payables commercial institutions december company notional amounts outstanding forward foreign exchange contracts cross currency interest rate swaps billion billion respectively december company notional amounts outstanding forward foreign exchange contracts cross currency interest rate swaps interest rate swaps billion billion billion respectively derivative instruments recorded balance sheet fair value changes fair value derivatives recorded period current earnings comprehensive income depending whether derivative designated part hedge transaction type hedge transaction designation cash flow hedge made entrance date derivative contract inception derivatives expected highly effective foreign exchange contracts designated cash flow hedges accounted forward method gainslosses associated contracts recognized income statement hedged item impacts earnings changes fair value derivatives recorded accumulated comprehensive income underlying transaction affects earnings reclassified earnings account hedged transaction gains losses associated interest rate swaps changes fair value hedged debt attributable changes interest rates recorded interest expense period occur effect immaterial fiscal years ended december december gains losses net investment hedge accounted currency translation account within accumulated comprehensive income portion excluded effectiveness testing recorded interest income expense using spot method ongoing basis company assesses whether derivative continues highly effective offsetting changes hedged items derivative longer expected highly effective hedge accounting discontinued company designated euro denominated notes issued may due dates ranging net investment hedge company 's investments certain international subsidiaries use euro functional currency order reduce volatility caused changes exchange rates december balance deferred net loss derivatives included accumulated comprehensive income million aftertax additional information see consolidated statements comprehensive income note company expects substantially amounts related forward foreign exchange contracts reclassified earnings next months result transactions expected occur period maximum length time company hedging transaction exposure months excluding interest rate contracts net investment hedges amount ultimately realized earnings may differ foreign exchange rates change realized gains losses ultimately determined actual exchange rates maturity derivative following table summary activity related derivatives hedges fiscal years ended december december net tax december december cost interest cost interest products rd income income products rd income income sales sold expense expense expense sales sold expense expense expense dollars millions effects fair value net investment cash flow hedging gain loss net investment hedging relationship cross currency interest rate swaps contracts amount gain loss recognized income derivative amount excluded effectiveness testing amount gain loss recognized aoci gain loss cash flow hedging relationship forward foreign exchange contracts amount gain loss reclassified aoci income amount gain loss recognized aoci cross currency interest rate swaps contracts amount gain loss reclassified aoci income amount gain loss recognized aoci fiscal years ended december december following amounts recorded consolidated balance sheet cumulative amount fair value hedging line item consolidated balance sheet carrying amount hedged liability adjustment included carrying amount hedged item included hedged liability dollars millions december december december december current portion longterm debt following table effect derivatives designated hedging instrument fiscal years ended december december location gain loss gainloss recognized income recognized dollars millions derivative income derivative derivatives designated hedging december december instruments income expense foreign exchange contracts following table effect net investment hedges fiscal years ended december december gainloss location gain loss reclassified gainloss reclassified recognized accumulated accumulated oci accumulated oci comprehensive income income income december december december december dollars millions interest income expense debt cross currency interest rate swaps interest income expense company holds equity investments readily determinable fair values equity investments without readily determinable fair values company measures equity investments readily determinable fair values cost minus impairment plus minus changes resulting observable price changes orderly transactions identical similar investment issuer following table summary activity related equity investments fiscal years ended december december december december changes fair value reflected sales non current dollars millions carrying value net income purchasesother carrying value assets equity investments readily determinable value equity investments without readily determinable value december december changes fair value reflected sales non current dollars millions carrying value net income purchasesother carrying value assetsequity investments readily determinable value equity investments without readily determinable value recorded incomeexpense includes impact currency fiscal years ended december december equity investments without readily determinable market values million million respectively changes fair value reflected net income result impairments million million respectively changes fair value reflected net income due changes observable prices fair value exit price would received sell asset paid transfer liability fair value marketbased measurement determined using assumptions market participants would use pricing asset liability accordance asc threelevel hierarchy prioritize inputs used measuring fair value levels within hierarchy described level highest priority level lowest fair value derivative financial instrument ie forward foreign exchange contracts interest rate contracts aggregation currency future cash flows discounted present value prevailing market interest rates subsequently converted us dollar current spot foreign exchange rate company believe fair values derivative instruments materially differ amounts could realized upon settlement maturity changes fair value material effect companys results operations cash flows financial position company also holds equity investments classified level debt securities classified level company holds acquisition related contingent liabilities based upon certain regulatory commercial events classified level whose values determined using discounted cash flow methodologies similar techniques determination fair value requires significant judgment estimations following three levels inputs used measure fair value level quoted prices active markets identical assets liabilities level significant observable inputs level significant unobservable inputs companys significant financial assets liabilities measured fair value fiscal year ended december december follows dollars millions level level level total total derivatives designated hedging instruments assets forward foreign exchange contracts interest rate contracts total liabilities forward foreign exchange contracts interest rate contracts total derivatives designated hedging instruments assets forward foreign exchange contracts liabilities forward foreign exchange contracts available sale investments equity investments debt securities liabilities contingent consideration gross net derivative reconciliation dollars millions total gross assets credit support agreement csa total net asset total gross liabilities credit support agreement csa total net liabilities summarized information changes liabilities contingent consideration follows dollars millions beginning balance changes estimated fair value additions payments ending balance assets liabilities classified level exception equity investments million classified level contingent consideration million classified level includes million million noncurrent assets fiscal years ending december december respectively includes million noncurrent liabilities fiscal years ending december includes cross currency interest rate swaps interest rate swaps classified noncurrent assets classified cash equivalents current marketable securities includes million primarily related auris health million million classified noncurrent liabilities december december december respectively includes million classified current liabilities december amounts recorded primarily research development expense see notes financial assets liabilities held carrying amount consolidated balance sheet borrowings components longterm debt follows effective effective rate rate dollars millions notes due b euro b euro notes due notes due notes due zero coupon convertible subordinated debentures due debentures due notes due notes due notes due notes due notes due b euro b euro notes due debentures due notes due notes due notes due mm euro mm euro notes due mm gbp mm gbp notes due notes due notes due notes due mm euro mm euro notes due notes due debentures due notes due notes due b euro b euro notes due notes due notes due debentures due notes due debentures due notes due notes due notes due notes due notes due subtotal less current portion total longterm debt weighted average effective rate translation rate december translation rate december excess fair value carrying value debt billion billion fair value longterm debt estimated using market prices corroborated quoted broker prices significant observable inputs company access substantial sources funds numerous banks worldwide september company secured new day credit facility total credit available company approximates billion expires september interest charged borrowings credit line agreements based either bids provided banks prime rate london interbank offered rates libor applicable market rate allowed terms agreement plus applicable margins commitment fees agreements material throughout company continued access liquidity commercial paper market shortterm borrowings current portion longterm debt amounted approximately billion end billion current portion longterm debt remainder principally represents local borrowing international subsidiaries throughout company continued access liquidity commercial paper market shortterm borrowings current portion longterm debt amounted approximately billion end billion current portion long term debt remainder principally represents local borrowing international subsidiaries aggregate maturities longterm debt obligations commencing dollars millions income taxes provision taxes income consists dollars millions currently payable us taxes international taxes total currently payable deferred us taxes international taxes total deferred provision taxes income includes billion deferred tax expense adoption deferred method account giltia comparison income tax expense us statutory rate companys effective tax rate follows dollars millions us international earnings taxes income tax rates us statutory rate international operations us taxes international income tax benefits sharebased compensation tcja related impacts effective rate periods presented company subsidiaries operating puerto rico various tax incentives international operations reflects impacts operations jurisdictions statutory tax rates different us particularly ireland switzerland puerto rico favorable impact effective tax rate compared us statutory rate amount also includes tax cost related revaluation deferred tax balances related change belgian statutory tax rate increasing tax provision approximately includes impact gilti tax foreignderived intangible income deduction foreign income taxable us tax code represents impact adjustments balances originally recorded part tcja provisional tax charge information provided includes us state local taxes provisionally recorded part tcja provisional charge approximately total effective tax rate tax rate decreased compared fiscal year tax rate addition impact swiss tax reform discussed detail primary drivers net decrease follows company reorganized ownership structure certain whollyowned international subsidiaries fiscal fourth quarter resulted reduction certain withholding local taxes previously recognized part provisional tax cuts jobs act tcja tax charge fiscal year finalized fiscal year following completion restructuring approval applicable local authorities company reversed deferred tax liability billion related deferred tax asset billion us foreign tax credits net deferred tax benefit billion decreasing annual effective tax rate benefit reflected tcja related impacts companys effective tax rate reconciliation impact agreement principle settle opioid litigation billion see note consolidated financial statements reduced us earnings taxes effective tax rate decreased companys annual effective tax rate approximately december fiscal year us treasury issued final foreign tax credit regulations resulted company revising amount foreign tax credits initially recorded fiscal year part provisional tcja tax charge result company recorded increased deferred tax asset related foreign tax credits approximately billion annual effective tax rate benefit reflected tcja related impacts companys effective tax rate reconciliation company reassessed uncertain tax positions related current irs audit increased unrecognized tax benefit billion liability increased annual effective tax rate approximately see section unrecognized tax benefits additional information positions related uncertain tax regarding international transfer pricing expense classified international operations companys effective tax rate reconciliation subsequent december company received agreed notices proposed adjustments nopas irs company believes adequately reserved potential exposures several onetime tax impacts resulted cumulative net tax benefit annual effective tax rate items included lifescan divestiture adjustment provisional tcja tax charge acceleration certain tax deductions part tax return income higher tax jurisdictions relative lower tax jurisdictions compared september swiss parliament approved federal act tax reform ahv financing traf may public referendum held switzerland approved federal reform proposals fiscal third quarter swiss federal council enacted traf became effective january federal transitional provisions traf allow companies certain conditions adjust tax basis adjustments fair value ie stepup used tax depreciation amortization purposes resulting deduction transitional period subsequent adjustment companys asset tax basis require review approval tax authorities traf also provides parameters enable swiss cantons establish localized tax rates regulations companies new cantonal tax parameters include favorable tax benefits patents additional research development tax deductions cantonal transitional provisions traf also expected allow companies elect either tax basis stepup similar federal transition benefit alternative statutory tax rate period exceed years company currently operations located various swiss cantons enactment may uniform substantive nature legislation timing enactment company recorded net tax expense billion increased effective tax rate fiscal year approximately net tax expense related federal certain cantonal enactments fiscal year consisting following provisions approximately billion tax expense relating remeasurement swiss deferred tax assets liabilities change federal cantonal tax rates enactment occurred december expense reflected international operations companys effective tax rate reconciliation billion deferred tax asset related estimated value federal tax basis stepup companys swiss subsidiaries assets benefit reflected international operations companys effective tax rate reconciliation approximately million us deferred tax expense relating gilti deferred tax liability resulting remeasurement swiss deferred tax assets liabilities new deferred tax asset federal stepup benefit reflected us tax international income companys effective tax rate reconciliation fiscal fourth quarter swiss federal tax administration issued authoritative guidance required company decrease estimated value federal tax basis stepup approximately billion determination made fiscal third quarter authoritative guidance relevant swiss tax authorities may issued future additional revisions may required fiscal period issued company currently assessing applying approval elective transition provisions several cantons includes discussions local tax authorities application new law company recorded estimated impact transitional provisions based best available information cantons enactment occurred company yet received final tax ruling december one canton company maintains significant operations yet enacted traf legislation amounts recorded fiscal year include estimates unenacted legislation february public referendum legislative change held canton legislation approved voters formal enactment expected fiscal first half company yet elected transitional provision canton however net financial benefit estimated billion billion fiscal first half us tax cuts jobs act tcja fiscal year united states enacted law new us tax legislation tcja law included provisions comprehensive overhaul corporate income tax code including reduction statutory corporate tax rate effective january legislation also eliminated reduced certain corporate income tax deductions well introduced new provisions taxed certain foreign income previously taxed united states tcja also included provision tax previously undistributed earnings us companies located foreign jurisdictions undistributed earnings form cash cash equivalents taxed rate earnings taxed rate tax payable years accrue interest payments began continue remaining balance end fiscal year approximately billion billion classified noncurrent reflected longterm taxes payable companys balance sheet balance account related receivables tax authorities expected received next months fourth quarter company recorded provisional tax cost approximately billion consisted primarily following components billion charge previously undistributed foreign earnings december billion deferred tax liability foreign local withholding taxes offset billion deferred tax asset us foreign tax credits repatriation substantially earnings billion tax benefit relating remeasurement us deferred tax assets liabilities impact tcja unrecognized tax benefits billion charge us state local taxes repatriation foreign earnings fiscal year company completed full assessment finalized accounting impact tcja company recorded net adjustments components provisional charge approximately billion revisions based updated estimates additional analysis management well applying interpretative guidance issued us department treasury facts circumstances existed tcja enactment date charge primarily related additional deferred tax liabilities foreign local withholding taxes remaining balance undistributed foreign earnings december provided provisional charge tcja also includes provisions tax gilti gilti described excess us shareholders total net foreign income deemed return tangible assets provided tcja fiscal year company elected treat gilti period expense deferred method recorded deferred tax cost approximately billion fiscal year related facts circumstances existed date tcja enactment see note information regarding income taxes accounting policies company reorganized ownership structure certain foreign subsidiaries resulted reduction certain foreign withholding taxes recognized part provisional tcja tax charge fourth quarter following completion restructuring result clarification swiss tax authorities regarding applicability withholding tax repatriation certain earnings company reversed deferred tax liability billion related deferred tax asset billion us foreign tax credits net deferred tax benefit billion benefit reflected tcja related impacts companys effective tax rate reconciliation effective tax rate decreased compared effective tax rate primarily driven approximately billion provisional tax charge recorded fourth quarter impact belgian statutory tax rate change increased effective rate additional drivers annual effective tax reduction us statutory corporate tax rate including effects tax elections resulted acceleration certain deductions tax return impact accelerated deductions decreased annual effective tax rate approximately impact adjustments provisional tcja charge including staff accounting bulletin sab adjustments internal restructuring decreased effective tax rate approximately gilti tax increased annual effective tax rate approximately excludes impact sab adjustment adoption deferred method gilti tax benefits received stockbased compensation fiscal reduced effective tax rate respectively fourth quarter company completed divestiture lifescan business see note consolidated financial statements increased company 's annual effective tax rate approximately income higher tax jurisdictions relative lower tax jurisdictions compared temporary differences carryforwards follows deferred tax deferred tax dollars millions asset liability asset liability employee related obligations stock based compensation depreciation amortization nondeductible intangibles international rd capitalized tax reserves liabilities income reported tax purposes net operating loss carryforward international undistributed foreign earnings global intangible lowtaxed income miscellaneous international miscellaneous us total deferred income taxes company whollyowned international subsidiaries cumulative net losses company believes likely subsidiaries generate future taxable income sufficient utilize deferred tax assets following table summarizes activity related unrecognized tax benefits dollars millions beginning year increases related current year tax positions increases related prior period tax positions decreases related prior period tax positions settlements lapse statute limitations end year million decrease related tcja unrecognized tax benefits billion december recognized would affect companys annual effective tax rate company conducts business files tax returns numerous countries currently tax audits progress number tax authorities respect united states internal revenue service irs completed audit tax years currently auditing tax years company currently expects completion audit settlement related tax liabilities fiscal year december company classified unrecognized tax benefits related interest approximately billion current liability accrued taxes income line consolidated balance sheet amount expected paid next months respect irs audit subsequent december company made payment approximately billion us treasury related estimated tax audit liability anticipation final settlement later fiscal completion tax audit may result additional adjustments companys unrecognized tax benefit liability major jurisdictions company conducts business years remain open tax audit go back year company believes possible tax audits may completed next twelve months taxing authorities jurisdictions outside united states however company able provide reasonably reliable estimate timing future tax payments relating uncertain tax positionsthe company classifies liabilities unrecognized tax benefits related interest penalties longterm liabilities except previously noted amounts related current united states irs audit interest expense penalties related unrecognized tax benefits classified income tax expense company recognized tax interest expense million million million respectively total amount accrued interest million million respectively employee related obligations end employee related obligations recorded consolidated balance sheets dollars millions pension benefits postretirement benefits postemployment benefits deferred compensation total employee obligations less current benefits payable employee related obligations noncurrent prepaid employee related obligations million million respectively included assets consolidated balance sheets pensions benefit plans company sponsors various retirement pension plans including defined benefit defined contribution termination indemnity plans cover employees worldwide company also provides postretirement benefits primarily health care eligible us retired employees dependents many international employees covered governmentsponsored programs cost company significant retirement plan benefits employees hired january primarily based employees compensation last three five years retirement number years service company announced us defined benefit plan amended adopt new benefit formula effective employees hired january benefits calculated using new formula based employee compensation total years service international subsidiaries plans funds deposited trustees annuities purchased group contracts reserves provided company typically fund retiree health care benefits advance may discretion company also right modify plans future company used december december respectively measurement date us international retirement benefit plans net periodic benefit costs companys defined benefit retirement plans benefit plans include following components retirement plans benefit plans dollars millions service cost interest cost expected return plan assets amortization prior service cost credit recognized actuarial losses curtailments settlements net periodic benefit cost amounts expected recognized net periodic benefit cost coming year companys defined benefit retirement plans postretirement plans dollars millions amortization net transition obligation amortization net actuarial losses amortization prior service credit unrecognized gains losses us pension plans amortized average remaining future service plan plans active employees amortized average life expectancy amortization gains losses us benefit plans determined using corridor greater market value assets accumulated postretirement benefit obligation total unamortized gains losses excess corridor amortized average remaining future service prior service costsbenefits us pension plans amortized average remaining future service plan participants time plan amendment prior service costbenefit us benefit plans amortized average remaining service full eligibility age plan participants time plan amendment following table represents weightedaverage actuarial assumptions retirement plans benefit plans worldwide benefit plans net periodic benefit cost service cost discount rate interest cost discount rate rate increase compensation levels expected longterm rate return plan assets benefit obligation discount rate rate increase compensation levels companys discount rates determined considering current yield curves representing high quality longterm fixed income instruments resulting discount rates consistent duration plan liabilities company 's methodology determining service interest cost uses duration specific spot rates along yield curve plans ' liability cash flows expected rates return plan asset assumptions represent company 's assessment longterm returns diversified investment portfolios globally assessment determined using projections external financial sources longterm historical averages actual returns asset class various asset class allocations market following table displays assumed health care cost trend rates individuals health care plans health care cost trend rate assumed next year rate cost trend rate assumed decline ultimate trend year rate reaches ultimate trend rate onepercentagepoint change assumed health care cost trend rates would following effect onepercentage onepercentagedollars millions point increase point decrease health care plans total interest service cost postretirement benefit obligation following table sets forth information related benefit obligation fair value plan assets yearend companys defined benefit retirement plans postretirement plans retirement plans benefit plans dollars millions change benefit obligation projected benefit obligation beginning year service cost interest cost plan participant contributions amendments actuarial gains losses divestitures acquisitions curtailments settlements restructuring benefits paid plan assets effect exchange rates projected benefit obligation end year change plan assets plan assets fair value beginning year actual return plan assets company contributions plan participant contributions settlements divestitures acquisitions benefits paid plan assets effect exchange rates plan assets fair value end year funded status end year amounts recognized companys balance sheet consist following noncurrent assets current liabilities noncurrent liabilities total recognized consolidated balance sheet end year amounts recognized accumulated comprehensive income consist following net actuarial loss prior service cost credit unrecognized net transition obligation total tax effects accumulated benefit obligations end year company offered voluntary lumpsum payment option certain eligible former employees vested participants us qualified defined benefit pension plan distribution lumpsums completed end fiscal amount distributed approximately million retirement plans benefit plans dollars millions amounts recognized net periodic benefit cost comprehensive income net periodic benefit cost net actuarial gain loss amortization net actuarial loss prior service cost credit amortization prior service cost credit effect exchange rates total lossincome recognized comprehensive income tax total recognized net periodic benefit cost comprehensive income company plans continue fund us qualified plans comply pension protection act international plans funded accordance local regulations additional discretionary contributions made deemed appropriate meet longterm obligations plans certain plans funding common practice funding provides economic benefit consequently company several pension plans funded company contributed million million us international pension plans respectively following table displays funded status company 's us qualified nonqualified pension plans international funded unfunded pension plans december december respectively us plans international plans qualified plans nonqualified plans funded plans unfunded plans dollars millions plan assets projected benefit obligation accumulated benefit obligation funded status projected benefit obligation accumulated benefit obligation plans accumulated benefit obligations excess plan assets accumulated benefit obligation projected benefit obligation plan assets billion billion billion respectively end billion billion billion respectively end following table displays projected future benefit payments companys retirement benefit plans dollars millions projected future benefit payments retirement plans benefit plans following table displays projected future minimum contributions unfunded retirement plans amounts donot include discretionary contributions company may elect make future dollars millions projected future contributions pension plan overseen local committee board responsible overall administration investment pension plans determining investment policies strategies goals committee board considers factors including local pension rules regulations local tax regulations availability investment vehicles separate accounts commingled accounts insurance funds etc funded status plans ratio actives retirees duration liabilities relevant factors including diversification liquidity local markets liquidity base currency majority companys pension funds open new entrants expected ongoing plans permitted investments primarily liquid andor listed little reliance illiquid nontraditional investments hedge funds companys retirement plan asset allocation end target allocations follows percent target plan assets allocation worldwide retirement plans equity securities debt securities total plan assets determination fair value plan assets plan established welldocumented process determining fair values fair value based upon quoted market prices available listed prices quotes available fair value based upon models primarily use inputs marketbased independently sourced market parameters including yield curves interest rates volatilities equity debt prices foreign exchange rates credit curves plan believes valuation methods appropriate consistent market participants use different methodologies assumptions determine fair value certain financial instruments could result different estimate fair value reporting date valuation hierarchy authoritative literature establishes threelevel hierarchy prioritize inputs used measuring fair value levels within hierarchy described table level highest priority level lowest net asset value nav based value underlying assets owned fund minus liabilities divided number shares outstanding financial instruments categorization within valuation hierarchy based upon lowest level input significant fair value measurement following description valuation methodologies used investments measured fair value shortterm investment funds cash quoted shortterm instruments valued closing price amount held deposit custodian bank investments investment vehicles valued using nav provided administrator fund nav quoted price market active classified level government agency securities limited number investments valued closing price reported major market individual securities traded quoted prices available active market investments classified within level valuation hierarchy quoted market prices available specific security fair values estimated using pricing models quoted prices securities similar characteristics discounted cash flows quoted market prices security available active market classified level debt instruments limited number investments valued closing price reported major market individual securities traded quoted prices available active market investments classified level quoted market prices available specific security fair values estimated using pricing models quoted prices securities similar characteristics discounted cash flows classified level level debt instruments priced based unobservable inputs equity securities equity securities valued closing price reported major market individual securities traded substantially equity securities classified within level valuation hierarchy commingled funds investment vehicles valued using nav provided fund administrator assets level category quoted market price insurance contracts instruments issued insurance companies fair value based negotiated value underlying investments held separate account portfolios well considering credit worthiness issuer underlying investments government assetbacked fixed income securities general insurance contracts classified level quoted prices observable inputs pricing assets assets represented primarily limited partnerships investment vehicles valued using nav provided fund administrator assets exchange listed actively traded classified level inactively traded assets classified level following table sets forth retirement plans ' investments measured fair value december december quoted prices significant active significant investments markets observable unobservable measured net identical assets inputs inputsa asset value level level level total assets dollars millions shortterm investment funds government agency securities debt instruments equity securities commingled funds insurance contracts assets investments fair value athe activity level assets significant years presented company 's benefit plans unfunded except us commingled funds level million million us shortterm investment funds level million million december december respectively fair value johnson johnson common stock directly held plan assets million total worldwide plan assets december million total worldwide plan assets december savings plan company voluntary k savings plans designed enhance existing retirement programs covering eligible employees company matches percentage employees contributions consistent provisions plan heshe eligible total company matching contributions plans million million million respectively capital treasury stock changes treasury stock treasury stock amounts millions except treasury stock shares thousands shares amount balance january employee compensation stock option plans repurchase common stock balance december employee compensation stock option plans repurchase common stock balance december employee compensation stock option plans repurchase common stock balance december aggregate shares common stock issued approximately shares end cash dividends paid per share compared dividends per share per share december company announced board directors approved share repurchase program authorizing company purchase billion company 's shares common stock share repurchase program completed september october company announced board directors approved share repurchase program authorizing company purchase billion company 's shares common stock share repurchase program completed july accumulated comprehensive income loss components comprehensive income loss consist following total gain accumulated foreign loss currency gainloss employee derivatives comprehensive dollars millions translation securities benefit plans hedges income loss january net changes december cumulative adjustment retained earnings net changes december net changes december per adoption asu financial instruments amounts accumulated comprehensive income presented net related tax impact foreign currency translation adjusted income taxes relates permanent investments international subsidiaries additional details oncomprehensive income see consolidated statements comprehensive income details reclassifications accumulated comprehensive income gainloss securities reclassifications released income expense net employee benefit plans reclassifications included net periodic benefit cost see note additional details gainloss derivatives hedges reclassifications earnings recorded account hedged transaction see note additional details international currency translation translation subsidiaries operating nonus dollar currencies company determined local currencies international subsidiaries functional currencies except highly inflationary economies defined compound cumulative rates inflation past three years substantial portion cash flows local currency majority company 's subsidiaries local currency functional currency consolidating international subsidiaries balance sheet currency effects recorded component accumulated comprehensive income equity account includes results translating certain balance sheet assets liabilities current exchange rates accounts historical rates except located highly inflationary economies argentina venezuela translation balance sheet accounts highly inflationary economies reflected operating results rollforward changes foreign currency translation adjustments included note net currency transaction gains losses included income expense losses million million million respectively earnings per share following reconciliation basic net earnings per share diluted net earnings per share fiscal years ended december december december millions except per share amounts basic net earnings per share average shares outstanding basic potential shares exercisable stock option plans less shares repurchased treasury stock method convertible debt shares adjusted average shares outstanding diluted diluted net earnings per share diluted net earnings per share calculation included dilutive effect convertible debt offset related reduction interest expense million aftertax diluted net earnings per share calculation excluded insignificant number shares related stock options exercise price options greater average market value companys stock diluted net earnings per share calculation included shares related stock options exercise price options less average market value company 's stock lease commitments company primarily operating leases space vehicles manufacturing equipment data processing equipment leases remaining lease terms ranging year years could include options extend leases reasonably certain operating lease costs approximately million million million respectively cash paid amounts included measurement lease liabilities million commitments finance leases significant supplemental information related leases follows weighted average remaining lease term discount rate operating leases years weighted average discount rate maturity lease liabilities related operating lease approximate minimum rental payments required operating leases initial remaining noncancelable lease terms excess one year december operating leases dollars millions total lease payments less interest present value lease liabilities supplemental information comparative periods december prior adoption asu approximate future minimum rental payments required operating leases initial remaining noncancelable lease terms excess one year dollars millions total supplemental balance sheet information related leases december follows dollars millions noncurrent operating lease rightofuse assets current operating lease liabilities noncurrent operating lease liabilities total operating lease liabilities common stock stock option plans stock compensation agreements december company stockbased compensation plans shares outstanding contracts company 's longterm incentive plan longterm incentive plan longterm incentive plan expired april options restricted shares granted subsequent date longterm incentive plan longterm incentive plan company may issue million shares common stock plus shares canceled expired forfeited issued longterm incentive plan subsequent april shares available future grants longterm incentive plan million end compensation cost charged income plans million million million respectively total income tax benefit recognized income statement sharebasedcompensation costs million million million respectively total unrecognized compensation cost million million million respectively weighted average period cost recognized years years years respectively sharebased compensation costs capitalized part inventory insignificant periods company settles employee benefit equity issuances treasury shares treasury shares replenished throughout year number shares used settle employee benefit equity issuances stock options stock options expire years date grant vest service periods range months years options granted average high low prices companys common stock new york stock exchange date grant fair value option award estimated date grant using blackscholes option valuation model uses assumptions noted following table grants expected volatility represents blended rate year weekly historical overall volatility rate week average implied volatility rate based atthemoney traded johnson johnson options life years grants historical data used determine expected life option riskfree rate based us treasury yield curve effect time grant average fair value options granted respectively fair value estimated based weighted average assumptions riskfree rate expected volatility expected life years expected dividend yield summary option activity plan december december december changes years ending dates presented aggregate weighted intrinsic average exercise value shares thousands outstanding shares price dollars millions shares january options granted options exercised options canceledforfeited shares december options granted options exercised options canceledforfeited shares december options granted options exercised options canceledforfeited shares december total intrinsic value options exercised million million million respectively following table summarizes stock options outstanding exercisable december shares thousands outstanding exercisableaverage average exercise price range options average life exercise price options exercise price average contractual life remaining years stock options outstanding december december average life years average life years respectively stock options exercisable december december average price average price respectively restricted share units performance share units company grants restricted share units vest service periods range months years company also grants performance share units paid shares johnson johnson common stock end threeyear performance period whether performance share units vest amount vest tied completion service periods range months years achievement threeyear period three equallyweighted goals directly align help drive longterm total shareholder return operational sales adjusted operational earnings per share relative total shareholder return number shares actually earned end threeyear period vary based actual performance target number performance share units granted fourth quarter company modified restricted share units scheduled vest january march modification guaranteed minimum aggregate value market value total expected payout amount awards expected vest period amount committed material companys overall financial position summary restricted share units performance share units activity plans december presented outstanding outstanding restricted share performance share shares thousands units units shares december granted issued canceledforfeitedadjusted shares december average fair value restricted share units granted respectively using fair market value date grant fair value restricted share units discounted dividends paid restricted share units vesting period fair value restricted share units issued million million million respectively weighted average fair value performance share units granted calculated using weighted average fair market value three component goals date grant fair values sales earnings per share goals performance share unit estimated date grant using fair market value shares time award discounted dividends paid performance share units vesting period fair value relative total shareholder return goal performance share unit estimated date grant using monte carlo valuation model fair value performance share units issued million million million respectively segments business geographic areas sales customers change dollars millions vs vs consumer baby care us international worldwide beauty us international worldwide oral care us international worldwide otc us international worldwide women 's health us international worldwide wound careother us international worldwide total consumer us international worldwide pharmaceutical immunology us international worldwide remicade us us exports international worldwide simponi simponi aria us international worldwide stelara us international worldwide tremfya us international worldwide immunology us international worldwide infectious diseases us international worldwide edurant rilpivirine us international worldwide prezista prezcobix rezolsta symtuza us international worldwide infectious diseases us international worldwide neuroscience us international worldwide concerta methylphenidate us international worldwide invega sustenna xeplion invega trinza trevicta us international worldwide risperdal consta us international worldwide neuroscience us international worldwide oncology us international worldwide darzalex us international worldwide imbruvica us international worldwide velcade us international worldwide zytiga abiraterone acetate us international worldwide oncologyus international worldwide pulmonary hypertension us international worldwide opsumit us international worldwide tracleer bosentan us international worldwide uptravi us international worldwide us international worldwide cardiovascular metabolism us international worldwide xarelto us international worldwide invokana invokamet us international worldwide procrit eprex us international worldwide us international worldwide total pharmaceuticalus international worldwide medical devices diabetes care us international worldwide diagnostics us international worldwide interventional solutions us international worldwide orthopaedics us international worldwide hips us international worldwide knees us international worldwide trauma us international worldwide spine us international worldwide surgery us international worldwide advanced us international worldwide generalus international worldwide specialty us international worldwide vision us international worldwide contact lenses us international worldwide surgical us international worldwide total medical devices us international worldwide worldwide us international worldwide percentage greater meaningful income tax identifiable assets dollars millions consumer pharmaceutical medical devices total less expense allocated segments general corporate worldwide total additions property depreciation plant equipment amortization dollars millions consumer pharmaceutical medical devices segments total general corporate worldwide total sales customers longlived assets dollars millions united states europe western hemisphere excluding us asiapacific africa segments total general corporate non longlived assets worldwide total see note description segments company operates export sales significant company utilized three wholesalers distributing products three segments represented approximately total consolidated revenues company three wholesalers distributing products three segments represented approximately total consolidated revenues company two wholesalers distributing products three segments represented approximately total consolidated revenues amounts allocated segments include interest income expense general corporate income expense general corporate includes cash cash equivalents marketable securities consumer segment includes gain billion related company 's previously held equity investment dr cilabo litigation expense billion restructuring charge billion pharmaceutical segment includes litigation expense billion including billion related agreement principle settle opioid litigation see note consolidated financial statements additional information regarding opioid litigation inprocess research development expense billion related alios asset research development expense billion upfront payment related argenx unrealized gain securities billion actelion acquisition related costs billion restructuring charge billion medical devices segment includes gain billion divestiture asp business restructuring related charge billion litigation expense billion auris health acquisition related costs billion consumer segment includes gain billion divestiture nizoral litigation expense billion pharmaceutical segment includes inprocess research development charge billion related alios xo assets corresponding xo contingent liability reversal billion actelion acquisition related costs billion unrealized loss securities billion gain billion divestiture certain nonstrategic pharmaceutical products medical devices segment includes net litigation expense billion restructuring related charge billion amo acquisition related costs billion gain billion divestiture lifescan business pharmaceutical segment includes billion actelion acquisition integration related costs inprocess research development expense billion litigation expense billion medical devices segment includes litigation expense billion restructuring related charge billion asset impairment billion primarily related insulin pump business billion amo acquisition related costs medical devices segment includes gain billion divestiture codman neurosurgery consumer segment includes gain billion divestiture compeed longlived assets include property plant equipment net respectively intangible assets goodwill net respectively selected quarterly financial data unaudited selected unaudited quarterly financial data years summarized first second third fourth first second third fourth dollars millions except per share data quarter quarter quarter quarter quarter quarter quarter quarter segment sales customers consumer pharmaceutical medical devices total sales gross profit earnings provision taxes income net earnings basic net earnings per share diluted net earnings per share first quarter includes gain billion aftertax billion beforetax related company 's previously held equity investment dr cilabo inprocess research development expense million aftertax million beforetax related alios asset litigation expense million aftertax million beforetax unrealized gain securities million aftertax million beforetax restructuring related charge million aftertax million beforetax acquisition related costs million aftertax million beforetax second quarter includes gain billion aftertax billion beforetax divestiture asp business litigation expense million aftertax million beforetax unrealized gain securities million aftertax million beforetax restructuring related charge million aftertax million beforetax acquisition related costs million aftertax million beforetax third quarter includes litigation expense million aftertax million beforetax related agreement principle settle opioid litigation restructuring related charge million aftertax million beforetax acquisition related costs million aftertax million beforetax million benefit aftertax impact tax legislation unrealized loss securities million aftertax million beforetax fourth quarter includes litigation expense million aftertax million beforetax unrealized gain securities million aftertax million beforetax restructuring related charge million aftertax million beforetax million benefit aftertax impact tax legislation acquisition related costs million aftertax million beforetax first quarter includes actelion acquisition related cost million aftertax million beforetax restructuring related charge million aftertax million beforetax second quarter includes litigation expense million aftertax million beforetax restructuring related charge million aftertax million beforetax third quarter includes inprocess research development expense million aftertax million beforetax related alios xo assets corresponding xo contingent liability reversal million tax restructuring related charge million aftertax million beforetax million benefit aftertax impact tax legislation fourth quarter includes litigation expense million aftertax million beforetax restructuring related charge million aftertax million beforetax million benefit aftertax impact tax legislation acquisitions divestitures certain businesses acquired billion cash billion liabilities assumed acquisitions accounted using acquisition method accordingly results operations included financial statements respective dates acquisition acquisitions primarily included dr cilabo japanese company focused marketing development distribution broad range dermocosmetic cosmetic skincare products auris health inc privately held developer robotic technologies initially focused lung cancer fdacleared platform currently used bronchoscopic diagnostic therapeutic procedures taris biomedical llc company specializing development novel drug delivery technology treatment bladder diseases including cancer company also acquired assets jointpoint inc privately held company navigation software improve surgical outcomes hip replacement excess purchase price estimated fair value tangible assets acquired amounted billion assigned identifiable intangible assets residual recorded goodwill january company acquired dr cilabo japanese company focused marketing development distribution broad range dermocosmetic cosmetic skincare products total purchase price approximately billion equates approximately billion using exchange rate japanese yen us dollar january acquisition completed series transactions included allcash tender offer acquire publicly held shares already held company per share company previously held ownership dr cilabo june company became legal owner dr cilabo completion tender offer procedure japan acquired company delisted tokyo stock exchange additionally fiscal first quarter company recognized pretax gain recorded income expense net approximately billion related company 's previously held equity investment dr cilabo company treated transaction business combination included consumer segment allocation purchase price included current period balance sheet based best estimate management preliminary subject change december fair value acquisition allocated primarily amortizable intangible assets billion goodwill billion liabilities billion subject subsequent valuation adjustments within measurement period adjustments made since date acquisition billion intangible assets accrued liabilities deferred taxes income property plant equipment offset goodwill amortizable intangible assets comprised brandtrademarks customer relationships weighted average life years goodwill primarily attributable synergies expected arise business acquisition expected deductible tax purposes april company completed acquisition auris health inc approximately billion net cash acquired additional contingent payments billion aggregate may payable upon reaching certain predetermined milestones auris health privately held developer robotic technologies initially focused lung cancer fdacleared platform currently used bronchoscopic diagnostic therapeutic procedures company treated transaction business combination included medical devices segment fair value acquisition allocated primarily amortizable nonamortizable intangible assets primarily iprd billion goodwill billion marketable securities billion liabilities assumed billion includes fair value contingent payments mentioned subject subsequent valuation adjustments within measurement period december valuation adjustments fair value contingent consideration billion probability success factor ranging used fair value calculation reflect inherent regulatory commercial risk contingent payments iprd discount rate applied approximately goodwill primarily attributable synergies expected arise business acquisition expected deductible tax purposes december company announced agreement acquire verily 's stake verb surgical inc transaction closed fiscal first quarter verb surgical inc subsidiary johnson johnson december subsequent fiscal year end company completed acquisition rights investigational compound bermekimab multiple dermatological indications along certain employees xbiotech inc purchase price billion xbiotech may eligible receive additional payments upon receipt certain commercialization authorizations transaction accounted business combination included pharmaceutical segment certain businesses acquired billion cash billion liabilities assumed acquisitions accounted using acquisition method accordingly results operations included financial statements respective dates acquisition acquisitions primarily included zarbees inc privately held company leader naturallybased consumer healthcare products benevir biopharm inc benevir privatelyheld biopharmaceutical company specializing development oncolytic immunotherapies orthotaxy privatelyheld developer softwareenabled surgery technologies including differentiated roboticassisted surgery solution company also acquired assets medicalenterprises distribution llc privately held healthcare technology firm focused surgical procedure innovation excess purchase price estimated fair value tangible assets acquired amounted billion assigned identifiable intangible assets residual recorded goodwill certain businesses acquired billion cash billion liabilities assumed acquisitions accounted using acquisition method accordingly results operations included financial statements respective dates acquisition acquisitions primarily included actelion ltd established leading franchise differentiated innovative products pulmonary arterial hypertension pah abbott medical optics amo whollyowned subsidiary abbott laboratories included ophthalmic products related cataract surgery laser refractive surgery consumer eye health neuravi limited privatelyheld medical device company develops markets medical devices neurointerventional therapy tearscience inc manufacturer products dedicated treating meibomian gland dysfunction sightbox inc privatelyheld company developed subscription vision care service connects consumers eye care professionals supply contact lenses torax medical inc privatelyheld medical device company manufactures markets linx reflux management system surgical treatment gastroesophageal reflux disease megadyne medical products inc privatelyheld medical device company develops manufactures markets electrosurgical tools excess purchase price estimated fair value tangible assets acquired amounted billion assigned identifiable intangible assets residual recorded goodwill amount approximately billion identified value iprd primarily associated acquisition actelion ltd value iprd calculated using cash flow projections discounted inherent risk projects company completed acquisition actelion ltd cash tender offer switzerland per share amounting billion net cash acquired part transaction immediately prior completion acquisition actelion spun drug discovery operations earlystage clinical development assets newly created swiss biopharmaceutical company idorsia ltd shares idorsia listed six swiss exchange six company held shares idorsia rights additional idorsia equity convertible loan principal amount approximately billion result idorsia raising additional capital july company currently holds shares idorsia rights additional idorsia equity convertible loan carrying value principal amount approximately billion convertible loan may converted idorsia shares subject certain restrictions follows aggregate shareholding idorsia shares result certain shareholders holding issued idorsia shares ii balance remaining amount within business days maturity date convertible loan year term idorsia undergoes change control transaction maturity loan remaining amount yet converted idorsia may elect settle remaining amount cash ordinary shares idorsia equity investment idorsia convertible loan recorded assets company 's consolidated balance sheet company also exercised option acquired act product within idorsia developed resistant hypertension currently phase clinical development company also entered agreement provide idorsia swiss franc denominated credit facility approximately million december idorsia made drawdowns credit facility actelion established leading franchise differentiated innovative products pulmonary arterial hypertension pah highly complementary existing portfolio company addition actelions specialty inmarket medicines latestage products consistent company 's efforts grow attractive complementary therapeutic areas serve patients serious illnesses significant unmet medical need fiscal second quarter company finalized purchase price allocation actelion individual assets acquired liabilities assumed using acquisition method following table presents amounts recognized assets acquired liabilities assumed acquisition date adjustments made second quarter dollars millions cash cash equivalents inventory accounts receivable current assets property plant equipment goodwill intangible assets deferred taxes noncurrent assets total assets acquired current liabilities deferred taxes noncurrent liabilities total liabilities assumed net assets acquired includes adjustment million writeup acquired inventory estimated fair value adjustments made since date acquisition billion deferred taxes billion current liabilities offset goodwill assets acquired recorded pharmaceutical segment acquisition actelion resulted approximately billion goodwill goodwill primarily attributable synergies expected arise acquisition goodwill expected deductible tax purposes purchase price allocation identifiable intangible assets follows dollars millions intangible assets definite lives patents trademarks total amortizable intangibles inprocess research development total intangible assets includes billion related valchlor one acquired products divested fiscal second quarter patents trademarks acquired comprised developed technology weighted average life years primarily based patent life marketed products intangible assets definite lives assigned asset lives ranging years inprocess research development intangible assets valued technology programs unapproved products value iprd calculated using probability adjusted cash flow projections discounted risk inherent projects discount rate applied acquisition accounted using acquisition method accordingly results operations actelion reported company 's financial statements beginning june date acquisition year ended december total sales net loss actelion date acquisition billion billion respectivelythe following table provides pro forma results operations fiscal year ended december actelion acquired january pro forma results include effect certain purchase accounting adjustments estimated changes depreciation amortization expense acquired tangible intangible assets however pro forma results include anticipated cost savings effects planned integration actelion accordingly amounts necessarily indicative results acquisition occurred dates indicated may occur future unaudited pro forma consolidated results dollars millions except per share data net sales net earnings diluted net earnings per common share company recorded actelion acquisition related costs tax approximately billion billion billion respectively recorded incomeexpense cost products sold company acquired abbott medical optics amo whollyowned subsidiary abbott laboratories billion net cash acquired acquisition included ophthalmic products related cataract surgery laser refractive surgery consumer eye health net purchase price primarily recorded amortizable intangible assets billion goodwill billion weighted average life total amortizable intangibles majority customer relationships approximately years goodwill primarily attributable synergies expected arise business acquisition deductible tax purposes intangible assets goodwill amounts based final purchase price allocation assets acquired recorded medical devices segment company completed acquisition synthes inc purchase price billion cash stock connection acquisition synthes inc company entered two accelerated share repurchase asr agreements company settled remaining liabilities asr agreements company believes transactions asr agreement series related internal transactions consummated tax efficient manner accordance applicable law possible internal revenue service could assert one contrary positions challenge transactions tax perspective challenged amount total purchase price synthes shares could treated subject applicable us tax approximately statutory rate company plus interest exception actelion ltd acquisition supplemental pro forma information accordance us gaap standards related business combinations goodwill intangible assets provided impact aforementioned acquisitions material effect companys results operations cash flows financial position divestitures company divested advanced sterilization products asp business fortive corporation aggregate value approximately billion consisting billion cash proceeds billion retained net receivables december assets held sale consolidated balance sheet billion inventory billion property plant equipment net billion goodwill company recognized pretax gain recorded income expense net approximately billion company divested lifescan inc business approximately billion retained certain net liabilities divestitures included nizoral roc certain nonstrategic pharmaceutical products pretax gains divestitures approximately billion company accepted binding offer form strategic collaboration jabil inc one worlds leading manufacturing services providers health care products technology products company expanding year relationship jabil produce range products within ethicon endosurgery depuy synthes businesses transaction includes transfer employees manufacturing sites majority transfers completed minor amount remaining december assets held sale consolidated balance sheet billion inventory property plant equipment net december assets held sale consolidated balance sheet billion inventory billion property plant equipment net additional details global supply chain restructuring see note consolidated financial statements company divestitures primarily included codman neurosurgery business integra lifesciences holdings corporation divestiture compeed hra pharma pretax gains divestitures approximately billion legal proceedings johnson johnson certain subsidiaries involved various lawsuits claims regarding product liability intellectual property commercial supplier indemnification matters governmental investigations legal proceedings arise time time ordinary course business company records accruals loss contingencies associated legal matters probable liability incurred amount loss reasonably estimated december company determined liabilities associated certain litigation matters probable reasonably estimated company accrued matters continue monitor related legal issue adjust accruals might warranted based new information developments accordance asc litigation regulatory matters discussed loss probable reasonably possible company unable estimate possible loss range loss beyond amounts already accrued amounts accrued legal contingencies often result complex series judgments future events uncertainties rely heavily estimates assumptions including timing related payments ability make estimates judgments affected various factors including among things whether damages sought proceedings unsubstantiated indeterminate scientific legal discovery commenced complete proceedings early stages matters present legal uncertainties significant facts dispute procedural jurisdictional issues uncertainty unpredictability number potential claims numerous parties involved extent adverse verdicts rendered company company record accrual loss determined probable reasonably estimated company 's opinion based examination matters experience date discussions counsel ultimate outcome legal proceedings net liabilities accrued company 's balance sheet expected material adverse effect company 's financial position however resolution increase accruals one matters reporting period may material adverse effect company 's results operations cash flows period product liability johnson johnson certain subsidiaries involved numerous product liability claims lawsuits involving multiple products claimants cases seek substantial compensatory available punitive damages company believes substantial defenses feasible predict ultimate outcome litigation time time even substantial defenses company considers isolated settlements based variety circumstances company established accruals product liability claims lawsuits compliance asc based currently available information cases may limited company accrues estimate legal defense costs needed defend matter costs probable reasonably estimated certain matters company accrued additional amounts estimated costs associated settlements damages losses product liability accruals represent projected product liability thousands claims around world different litigation environments different fact patterns changes accruals may required future additional information becomes available significant cases include depuy asr xl acetabular system depuy asr hip resurfacing system pinnacle acetabular cup system pelvic meshes risperdal xarelto body powders containing talc primarily johnsons baby powder invokana ethicon physiomesh flexible composite mesh december united states approximately plaintiffs direct claims pending lawsuits regarding injuries allegedly due depuy asr xl acetabular system depuy asr hip resurfacing system respect pinnacle acetabular cup system respect pelvic meshes respect risperdal respect xarelto respect body powders containing talc respect invokanaand respect ethicon physiomesh flexible composite mesh august depuy orthopaedics inc depuy announced worldwide voluntary recall asr xl acetabular system depuy asr hip resurfacing system used hip replacement surgery claims personal injury made depuy johnson johnson number pending lawsuits expected fluctuate certain lawsuits settled dismissed additional lawsuits filed cases filed federal courts united states organized multi district litigation united states district court northern district ohio litigation also filed countries outside united states primarily united kingdom canada australia ireland germany india italy november depuy reached agreement courtappointed committee lawyers representing asr hip system plaintiffs establish program settle claims eligible asr hip patients united states surgery replacetheir asr hips known revision surgery august depuy reached additional agreements february march extended settlement program include asr hip patients revision surgeries august prior february settlement program resolved claims therefore bringing resolution significant asr hip litigation activity united states however lawsuits united states remain settlement program address litigation outside united states australia class action settlement reached resolved claims majority asr hip patients country canada company reached agreements settle two pending class actions approved qubec superior court supreme court british columbia company continues receive information respect potential additional costs associated recall worldwide basis company established accruals costs associated united states settlement program depuy asr hiprelated product liability litigation claims personal injury also made depuy orthopaedics inc johnson johnson collectively depuy relating pinnacle acetabular cup system used hip replacement surgery product liability lawsuits continue filed company continues receive information respect potential costs anticipated number cases cases filed federal courts united states organized multidistrict litigation united states district court northern district texas litigation also filed state courts countries outside united states several adverse verdicts rendered depuy one reversed appeal remanded retrial first quarter depuy established united states settlement program resolve cases part settlement program adverse verdicts settled company established accrual product liability litigation associated pinnacle acetabular cup system related settlement program claims personal injury made ethicon inc ethicon johnson johnson arising ethicon 's pelvic mesh devices used treat stress urinary incontinence pelvic organ prolapse company continues receive information respect potential costs additional cases cases filed federal courts united states organized multidistrict litigation mdl united states district court southern district west virginia mdl court remanding cases trial jurisdictions case originally filed additional pelvic mesh lawsuits filed remain outside mdl company settled otherwise resolved majority united states cases estimated costs associated settlements remaining cases reflected company 's accruals addition class actions individual personal injury cases claims commenced various countries outside united states including claims cases united kingdom netherlands belgium class actions israel australia canada seeking damages alleged injury resulting ethicon 's pelvic mesh devices november federal court australia issued judgment regarding findings respect liability relation three lead applicants generally relation design manufacture pre postmarket assessments testing supply promotion devices australia used treat stress urinary incontinence pelvic organ prolapse orders determining damages amounts awarded three lead applicants expected first quarter respect group members individual case assessment process require proof use causally related loss class actions canada expected discontinued result settlement group cases subject court approval discontinuance company established accruals respect product liability litigation associated ethicon 's pelvic mesh products following june worldwide market withdrawal ethicon physiomesh flexible composite mesh claims personal injury made ethicon inc johnson johnson alleging personal injury arising use hernia mesh device cases filed federal courts united states organized multidistrict litigation mdl united states district court northern district georgia multicounty litigation mcl also formed new jersey state court assigned atlantic county cases pending new jersey addition matters mdl mcl additional lawsuits pending united states district court southern district ohio part mdl polypropylene mesh devices manufactured cr bard inc lawsuits pending outside united states along ethicon physiomesh lawsuits number filings related proceed mesh proceed ventral patch products march new jersey supreme court entered order consolidating proceed proceed ventral patch cases mcl atlantic county superior court additional cases filed various federal state courts us jurisdictions outside us company continues receive information respect potential costs anticipated number cases company established accruals respect product liability litigation associated ethicon physiomesh flexible composite mesh proceed mesh proceed ventral patch products september plaintiffs attorney filed application new jersey supreme court seeking centralized management prolene polypropylene hernia system cases new jersey supreme court granted plaintiffs application january transferred mcl atlantic county superior courtclaims personal injury made janssen pharmaceuticals inc johnson johnson arising use risperdal indicated treatment schizophrenia acute manic mixed episodes associated bipolar disorder irritability associated autism related compounds lawsuits primarily filed state courts pennsylvania california missouri actions pending various courts united states canada product liability lawsuits continue filed company continues receive information respect potential costs anticipated number cases company successfully defended number cases verdicts company including recent verdict october billion punitive damages related one single plaintiff subsequently reduced january million trial judge company appeal final judgment company settled otherwise resolved many united states cases costs associated settlements reflected company 's accruals claims personal injury arising use xarelto oral anticoagulant made janssen pharmaceuticals inc jpi johnson johnson jj jpi 's collaboration partner xarelto bayer ag certain affiliates cases filed federal courts united states organized multidistrict litigation united states district court eastern district louisiana addition cases filed state courts across united states many cases consolidated state mass tort litigation philadelphia pennsylvania coordinated proceeding los angeles california class action lawsuits also filed canada march jpi jj announced agreement principle settle xarelto cases united states settlement agreement executed may settlement became final december resolve majority cases pending united states company established accruals costs associated united states settlement program xarelto related product liability litigation personal injury claims alleging talc causes cancer made johnson johnson consumer inc johnson johnson arising use body powders containing talc primarily johnsons baby powder number pending product liability lawsuits continues increase company continues receive information respect potential costs anticipated number cases lawsuits primarily filed state courts missouri new jersey california well outside united states cases filed federal courts united states organized multidistrict litigation united states district court district new jersey multidistrict litigation parties moved exclude experts known daubert motions court held daubert hearings midjuly final round briefing submitted court parties awaiting decision company successfully defended number cases verdicts company including verdict july billion company believes strong grounds appeal overturn verdicts company established accrual primarily defense costs connection product liability litigation associated body powders containing talc february companys talc supplier imerys talc america inc two affiliates imerys talc vermont inc imerys talc canada inc collectively imerys filed voluntary chapter petition commencing reorganization united states bankruptcy code united states bankruptcy court district delaware imerys bankruptcy imerys bankruptcy relates imerys potential liability personal injury exposure talcum powder sold imerys talc claims bankruptcy filing imerys noted certain claims alleges company indemnification rights joint insurance proceeds based claims well indemnity insurance claims company imerys company petitioned united states district court district delaware establish federal jurisdiction state court talc lawsuits bankruptcy code company 's petition denied state court talc lawsuits removed federal court basis remanded company formally proposed resolve imerys ' companys obligations arising talc claims agreeing assume defense litigation talc claims involving company 's products lifting automatic stay enable talc claims proceed outside bankruptcy forum company agreeing settle pay judgment imerys waiving companys indemnification claims imerys discussions imerys company issue remain ongoing february securities class action lawsuit filed johnson johnson certain named officers united states district court district new jersey alleging johnson johnson violated federal securities laws failing adequately disclose alleged asbestos contamination body powders containing talc primarily johnson 's baby powder purchasers johnson johnsons shares suffered losses result plaintiffs seeking damages april company moved dismiss complaint briefing motion complete august december court denied part motion dismiss october shareholder derivative lawsuit filed johnson johnson nominal defendant current directors defendants united states district court district new jersey alleging breach fiduciary dutiesrelated alleged asbestos contamination body powders containing talc primarily johnsons baby powder johnson johnson suffered damages result alleged breaches june shareholder filed additional complaint initiating summary proceeding new jersey state court books records inspection august johnson johnson responded books records complaint filed cross motion dismiss september plaintiff replied court heard oral argument court yet ruled books records action september united states district court district new jersey granted defendants motion dismiss shareholder derivative lawsuit dismissed complaint without prejudice october shareholder filed notice appeal united states court appeals third circuit january shareholder voluntarily dismissed appeal prejudice four additional shareholder derivative lawsuits filed new jersey making similar allegations company current directors certain officers january two erisa class action lawsuits filed participants johnson johnson savings plan johnson johnson pension benefits committee certain named officers united states district court district new jersey alleging defendants breached fiduciary duties offering johnson johnson stock johnson johnson savings plan investment option imprudent failures disclose alleged asbestos contamination body powders containing talc primarily johnsons baby powder plaintiffs seeking damages injunctive relief defendants filed motion dismiss lawsuit pending united states district court central district california alleging violations proposition californias unfair competition law false advertising law concerning johnsons baby powder june plaintiffs filed motion voluntary dismissal proposition action company opposed motion extent would allow plaintiffs counsel refile claims new plaintiffs court granted plaintiffs motion conditioned upon payment attorneys fees costs court entered award attorneys fees costs october case dismissed without prejudice another lawsuit alleging violations proposition californias consumer legal remedies act relating johnsons baby powder filed superior court california county san diego july company filed notice removal united states district court southern district california plaintiffs filed second amended complaint shortly thereafter october company moved dismiss second amended complaint failure state claim upon relief may granted primarily basis plaintiffs failed comply proposition mandatory presuit notice requirement applies even plaintiff asserts indirect proposition claim response motions plaintiffs filed third amended complaint december company moved dismiss third amended complaint failure state claim upon relief may granted addition company received preliminary inquiries subpoenas produce documents regarding matters senator murray member senate committee health education labor pensions department justice securities exchange commission us congressional subcommittee economic consumer policy company cooperating government inquiries continues produce documents response claims personal injury made number johnson johnson companies including janssen pharmaceuticals inc johnson johnson arising use invokana prescription medication indicated improve glycemic control adults type diabetes lawsuits filed federal courts united states organized multidistrict litigation united states district court district new jersey cases also filed state courts class action lawsuits filed canada product liability lawsuits continue filed company continues receive information respect potential costs anticipated number cases company settled otherwise resolved many cases claims united states costs associated settlements reflected company 's accruals intellectual property certain subsidiaries johnson johnson subject time time legal proceedings claims related patent trademark intellectual property matters arising businesses many matters involve challenges coverage andor validity patents various products allegations certain companys products infringe patents third parties although subsidiaries believe substantial defenses challenges allegations respect significant patents assurance outcome matters loss cases could adversely affect ability subsidiaries sell products result loss sales due loss market exclusivity require payment past damages future royalties may result noncash impairment charge associated intangible asset significant matters described belowmedical devices march medinol ltd medinol filed patent infringement lawsuit cordis corporation cordis johnson johnson united states district court southern district new york alleging cordiss sales cypher cypher select stents made united states since willfully infringed four medinol 's patents directed geometry articulated stents although johnson johnson since sold cordis retained liability case trial january district court dismissed case finding medinol unreasonably delayed bringing claims laches defense september district court denied motion medinol vacate judgment grant new trial medinol appealed decision united states court appeals federal circuit march united states supreme court held laches defense available patent cases april united states court appeals federal circuit remanded case back district court reconsider medinols motion new trial march district court denied medinols motion new trial april medinol filed notice appeal november medidea llc medidea filed patent infringement lawsuit depuy orthopaedics inc united states district court northern district illinois alleging infringement attune knee system april medidea filed amended complaint adding depuy synthes products inc depuy synthes sales inc named defendants collectively depuy medidea alleges infringement united states patent nos relating posterior stabilized knee systems specifically medidea alleges sofcamtm contact feature attune posterior stabilized knee products infringes patentsinsuit medidea seeking monetary damages injunctive relief june case transferred united states district court district massachusetts claim construction hearing held october claim construction order issued november december medidea stipulated noninfringement patents based district courts claim construction reserving right appeal construction leaving patent issue district court january district court stayed case pending decision inter partes review proceeding patent see december depuy synthes products inc filed petition inter partes review united states patent trademark office uspto seeking invalidate two claims patent asserted district court litigation june uspto instituted review claims hearing held march april uspto issued decision upholding validity patent may depuy filed motion summary judgment noninfringement claims patent november judgment entered favor depuy december medidea filed notice appeal december ethicon endosurgery inc ethicon endosurgery llc known ethicon llc sued covidien inc united states district court district massachusetts seeking declaration united states patent nos patent patent either invalid infringed ethicons enseal x large jaw tissue sealer product april covidien lp covidien sales llc covidien ag collectively covidien answered counterclaimed denying allegations asserting willful infringement patent patent united states patent nos patent patent seeking damages injunction covidien filed motion preliminary injunction denied october parties entered joint stipulations patent patent remain dispute trial began september closing arguments heard march december dr ford albritton sued acclarent inc acclarent united states district court northern district texas alleging acclarents relieva spin relievea spinplus products infringe us patent patent dr albritton also alleges breach contract fraud true owner acclarents us patent december acclarent filed petition inter partes review ipr united states patent trademark office uspto challenging validity patent uspto instituted ipr july july uspto ruled favor albritton ipr finding acclarent met burden proof challenged claims invalid october court appeals affirmed usptos patent trial appeal board june parties filed cross motions summary judgment district court parties awaiting decision district court trial scheduled april november board regents university texas system tissuegen inc collectively ut filed lawsuit united states district court western district texas ethicon inc ethicon us llc alleging manufacture sale vicryl plus antibacterial sutures monocryl plus antibacterial sutures pds plus antibacterial sutures stratafix pds antibacterial sutures stratafix monocryl plus antibacterial suturesinfringe plaintiffs united states patent nos patent directed implantable polymer drug releasing biodegradable fibers containing therapeutic agent ut seeking damages injunction december ethicon filed petitions uspto seeking inter partes review ipr asserted patents petitions stayed uspto pending decision us supreme court unrelated case ut dismissed patent suit longer accuses pds plus antibacterial sutures stratafix pds plus antibacterial sutures infringement district court trial scheduled june august intuitive surgical inc intuitive surgical operations inc intuitive filed patent infringement suit auris health inc auris united states district court district delaware suit intuitive alleges willful infringement us patent nos patent patent patent patent patent patent patent patent based auris monarch platform auris filed petitions inter partes review uspto regarding patents december uspto instituted review patent denied review patent district court trial scheduled begin january august rsb spine llc rsb spine filed patent infringement suit depuy synthes inc united states district court district delaware october rsb spine amended complaint change named defendants depuy synthes sales inc depuy synthes products inc suit rsb spine alleges willful infringement united states patent nos one following products zeropva spacer zerop spacer zerop natural plate synfix lr spacer synfix evolution system rsb spine seeks monetary damages injunctive relief november suit consolidated pretrial purposes patent infringement suits brought rsb spine united states district court district delaware life spine inc medacta usa inc precision spine inc xtant medical holdings inc pharmaceutical august sandoz ltd hexal ag collectively sandoz filed lawsuit english high court gd searle llc pfizer company searle janssen sciences ireland uc jsi alleging searles supplementary protection certificate spcgb spc exclusively licensed jsi invalid revoked janssencilag limited sells prezista darunavir united kingdom pursuant license october searle jsi counterclaimed sandoz threatened infringement spc based statements plans launch generic darunavir united kingdom sandoz admitted generic darunavir product would infringe spc found valid searle jsi seeking order enjoining sandoz marketing generic darunavir expiration spc following trial april court entered decision holding spc valid granting final injunction sandoz appealed courts decision injunction stayed pending appeal january court referred issue appeal court justice european union cjeu stayed proceedings pending cjeus ruling issue december parties entered settlement agreement april acerta pharma bv astrazeneca uk ltd astrazeneca pharmaceuticals lp filed patent infringement lawsuit united states district court district delaware pharmacyclics llc abbvie inc collectively abbvie alleging manufacture sale imbruvica infringes us patent janssen biotech inc commercializes imbruvica jointly abbvie intervened action november october parties entered settlement agreement remicade related cases august celltrion healthcare co ltd celltrion inc collectively celltrion filed application united states food drug administration fda approval make sell infliximab biosimilar march janssen biotech inc jbi filed lawsuit united states district court district massachusetts celltrion hospira healthcare corporation hospira exclusive marketing rights celltrions infliximab biosimilar united states seeking among things declaratory judgment biosimilar product infringes potentially infringes several jbi patents including united states patent relating remicade infliximab patent united states patent patent directed cell culture media used make celltrions biosimilar august district court granted celltrions hospiras motions summary judgment invalidity patent jbi appealed decisions united states court appeals federal circuit january federal circuit dismissed appeal moot based affirmance decision usptos patent trial appeal board affirming invalidity patent june jbi filed two additional patent infringement lawsuits asserting patent one celltrion hospira united states district court district massachusetts hyclone laboratories inc manufacturer cell culture media celltrion uses make biosimilar product united states district court forthe district utah jbi seeks monetary damages relief october district court massachusetts action denied celltrion hospiras motion dismiss lack standing july district court massachusetts action granted celltrions motion summary judgment noninfringement entered order dismissing lawsuit celltrion hospira jbi appealed united states court appeals federal circuit celltrion hospira crossappealed standing issue hearing appeal crossappeal scheduled march litigation hyclone utah stayed pending outcome massachusetts actions fda approved first infliximab biosimilar sale united states number products launched litigation filers abbreviated new drug applications andas following summarizes lawsuits pending generic companies filed abbreviated new drug applications andas fda undertaken similar regulatory processes outside united states seeking market generic forms products sold various subsidiaries johnson johnson prior expiration applicable patents covering products andas typically include allegations noninfringement invalidity applicable patents event subsidiaries successful action automatic statutory stay andas expires united states district court rulings obtained thirdparty companies involved would ability upon approval fda introduce generic versions products market resulting potential substantial market share revenue losses applicable products may result noncash impairment charge associated intangible asset addition time time subsidiaries may settle types actions settlements involve introduction generic versions products issue market prior expiration relevant patents inter partes review ipr process united states patent trademark office uspto created america invents act also used times generic companies conjunction andas lawsuits challenge applicable patents zytiga july janssen biotech inc janssen oncology inc janssen research development llc collectively janssen btg international ltd btg initiated patent infringement lawsuit main action united states district court district new jersey number generic companies certain affiliates andor suppliers filed andas seeking approval market generic version zytiga mg expiration united states patent patent generic companies include amneal pharmaceuticals llc amneal pharmaceuticals new york llc collectively amneal apotex inc apotex corp collectively apotex citron pharma llc citron dr reddys laboratories ltd dr reddys laboratories inc collectively dr reddys mylan pharmaceuticals inc mylan inc collectively mylan par pharmaceuticals inc par pharmaceutical companies inc collectively par teva pharmaceuticals usa inc teva wockhardt bio ag wockhardt usa llc wockhardt ltd collectively wockhardt westward pharmaceutical corp westward hikma pharmaceuticals llc hikma janssen btg also initiated patent infringement lawsuits united states district court district new jersey amerigen pharmaceuticals limited amerigen may glenmark pharmaceuticals inc glenmark june filed anda seeking approval market generic version zytiga expiration patent lawsuits consolidated main action august janssen btg filed additional jurisdictional protective lawsuit mylan defendants united states district court northern district west virginia stayed august janssen btg initiated patent infringement lawsuit united states district court district new jersey teva filed anda seeking approval market generic version zytiga mg expiration patent lawsuit consolidated main action december janssen btg entered settlement agreement glenmark february janssen btg filed patent infringement lawsuit msn pharmaceuticals inc msn laboratories private limited collectively msn united states district court district new jersey based anda seeking approval generic version zytiga prior expiration patent february action stayed pending outcome main action april janssen btg entered settlement agreement apotexin october united states district court district new jersey issued ruling invalidating asserted claims patent court held patent claims would infringed patent valid janssen appealed courts decision november janssen btg initiated patent infringement lawsuit united states district court district new jersey qilu pharmaceutical co ltd qilu pharma inc collectively qilu filed anda seeking approval market generic version zytiga expiration patent janssen seeking order enjoining qilu marketing generic version zytiga expiration patent november united states court appeals federal circuit denied janssens request injunction pending appeal result several generic versions zytiga entered market several generic companies including amerigen argentum pharmaceuticals llc argentum mylan wockhardt actavis amneal dr reddys sun teva westward hikma filed petitions inter partes review ipr uspto seeking invalidate patent january uspto issued decisions finding patent claims unpatentable janssen requested rehearing december uspto denied janssens request rehearing ipr decisions janssen filed appeal consolidated abovementioned appeal decision united states district court district new jersey may federal circuit issued decision affirming uspto 's decision wockhardt ipr patent claims unpatentable dismissed remaining appeals moot subsequently janssen dismissed lawsuits msn qilu november janssen initiated notice application section patented medicines notice compliance regulations apotex inc apotex minister health canada response apotexs filing abbreviated new drug submission ands seeking approval market generic version zytiga expiration canadian patent patent final hearing concluded may october court issued order prohibiting canadian minister health approving apotexs ands expiration patent november apotex filed appeal january janssen initiated notice application section patented medicines notice compliance regulations apotex minister health canada response apotexs filing abbreviated new drug submission ands seeking approval market filmcoated generic version zytiga expiration patent january janssen initiated notice application section patented medicines notice compliance regulations pharmascience inc pharmascience minister health canada response pharmasciences filing abbreviated new drug submission ands seeking approval market generic version zytiga mg expiration patent final hearing scheduled begin october november janssen initiated notice application section patented medicines notice compliance regulations pharmascience minister health canada response pharmasciences filing ands seeking approval market generic version zytiga mg expiration patent final hearing scheduled begin october january janssen initiated notice application section patented medicines notice compliance regulations sandoz canada inc sandoz minister health canada response sandozs filing abbreviated new drug submission ands seeking approval market generic version zytiga expiration canadian patent july parties entered settlement agreement june janssen initiated notice application section patented medicines notice compliance regulations dr reddy 's laboratories ltd dr reddy 's laboratories inc collectively drl minister health canada response apotexs filing abbreviated new drug submission ands seeking approval market generic version zytiga expiration canadian patent final hearing scheduled begin october canadian actions janssen seeking order prohibiting minister health issuing notice compliance respect defendants andss expiration janssens patentxarelto beginning october janssen pharmaceuticals inc jpi bayer pharma ag bayer intellectual property gmbh collectively bayer filed patent infringement lawsuits united states district court district delaware number generic companies filed andas seeking approval market generic versions xarelto expiration bayers united states patent nos relating xarelto jpi exclusive sublicensee asserted patents following generic companies named defendants aurobindo pharma limited aurobindo pharma usa inc collectively aurobindo breckenridge pharmaceutical inc breckenridge invagen pharmaceuticals inc invagen micro labs usa inc micro labs ltd collectively micro mylan pharmaceuticals inc mylan prinston pharmaceuticals inc sigmapharm laboratories llc sigmapharm torrent pharmaceuticals limited torrent pharma inc collectively torrent trial concluded april july district court entered judgment mylan sigmapharm holding asserted compound patent valid infringed september district court entered judgment remaining defendants none defendants appealed judgment beginning april jpi bayer intellectual property gmbh bayer ag collectively bayer ag filed patent infringement lawsuits united states district court district delaware number generic companies filed andas seeking approval market generic versions xarelto expiration bayer ags united states patent relating xarelto jpi exclusive sublicensee asserted patent following generic companies named defendants alembic pharmaceuticals limited alembic global holding sa alembic pharmaceuticals inc alembic aurobindo breckenridge invagen lupin limited lupin pharmaceuticals inc collectively lupin micro mylan sigmapharm taro pharmaceutical industries ltd taro pharmaceuticals usa inc collectively taro torrent lupin counterclaimed declaratory judgment noninfringement invalidity united states patent lupin dismissed counterclaims provided covenant sue patent aurobindo taro torrent micro breckenridge invagen sigmapharm lupin alembic agreed cases stayed bound outcome final judgment rendered defendants cases consolidated discovery trial trial began april closing arguments heard june december jpi bayer ag filed patent infringement lawsuit united states district court district delaware teva pharmaceuticals usa inc teva pharmaceutical industries ltd collectively teva filed anda seeking approval market generic version xarelto expiration bayer ags patent case teva consolidated cases purposes teva agreed case stayed bound outcome final judgment rendered defendants may mylan filed petition inter partes review uspto seeking invalidate patent december uspto issued decision denying institution mylans petition inter partes review may jpi bayer filed suit macleods pharmaceuticals ltd macleods pharma usa inc collectively macleods alleging infringement patent case macleods consolidated cases purposes macleods agreed case stayed bound outcome final judgment rendered defendants june jpi bayer filed suit accord healthcare inc accord healthcare ltd intas pharmaceuticals ltd collectively accord alleging infringement patent august jpi bayer filed suit sunshine lake pharma co ltd hec pharm usa inc alleging infringement patent october jpi bayer entered settlement agreement mylan november jpi bayer entered settlement agreement breckenridge december jpi bayer entered settlement agreements accord micro sigmapharm sunshine torrent january jpi bayer entered settlement agreement macleods consolidated cases involving alembic aurobindo invagen lupin taro teva stayed march lawsuits jpi seeking order enjoining defendants marketing generic versions xareltobefore expiration relevant patents prezista may janssen products lp janssen sciences ireland uc collectively janssen initiated patent infringement lawsuit united states district court district new jersey dr reddys laboratories inc dr reddys laboratories ltd laurus labs ltd pharmaq inc collectively drl filed anda seeking approval market generic versions prezista expiration united states patent nos february parties entered settlement agreement december janssen initiated patent infringement lawsuit united states district court district new jersey amneal pharmaceuticals llc amneal pharmaceuticals company gmbh amneal pharmaceuticals new york llc amneal pharmaceuticals pvt ltd raks pharma pvt ltd collectively amneal filed anda seeking approval market generic versions prezista expiration united states patent nos april parties entered settlement agreement january janssen products lp janssen sciences ireland unlimited company collectively janssen initiated patent infringement lawsuit united states district court district new jersey zydus pharmaceuticals usa inc cadila healthcare ltd collectively zydus filed anda seeking approval market generic version prezista expiration united states patent nos janssen seeking order enjoining zydus marketing generic version prezista expiration relevant patents invokanainvokametinvokamet xr beginning july janssen pharmaceuticals inc janssen research development llc cilag gmbh international janssen pharmaceutica nv collectively janssen mitsubishi tanabe pharma corporation mtpc filed patent infringement lawsuits united states district court district new jersey united states district court district colorado united states district court district delaware number generic companies filed andas seeking approval market generic versions invokana andor invokamet expiration mtpcs united states patent nos patent andor patent relating invokana invokamet janssen exclusive licensee asserted patents following generic companies named defendants apotex inc apotex corp apotex aurobindo pharma usa inc aurobindo macleods pharmaceuticals ltd macleods pharma usa inc invagen pharmaceuticals inc invagen prinston pharmaceuticals inc dr reddys laboratories inc dr reddys laboratories ltd hetero usa inc hetero labs limited unitv hetero labs limited msn laboratories private ltd msn pharmaceuticals inc laurus labs ltd indoco remedies ltd zydus pharmaceuticals usa inc zydus sandoz inc sandoz teva pharmaceuticals usa inc lupin ltd lupin pharmaceuticals inc lupin beginning july janssen mtpc filed patent infringement lawsuits united states district court district new jersey united states district court district colorado sandoz invagen filed andas seeking approval market generic versions invokana andor invokamet expiration mtpcs united states patent patent relating invokana invokamet zydus filed andas seeking approval market generic versions invokana invokamet expiration patent mtpc 's united states patent relating invokana invokamet mtpcs united states patent relating invokamet patent aurobindo filed anda seeking approval market generic version invokana expiration patent patent relating invokana janssen exclusive licensee asserted patents october colorado lawsuits sandoz dismissed december delaware lawsuits apotex teva dismissed april janssen mtpc filed patent infringement lawsuit united states district court district new jersey prinston filed anda seeking approval market generic version invokana expiration patent relating invokana february janssen mtpc filed patent infringement lawsuit united states district court district new jersey lupin filed anda seeking approval market generic version invokamet xr expiration patent patent relating invokamet xr july janssen mtpc filed patent infringement lawsuit united states district court district newjersey msn filed anda seeking approval market generic version invokamet xr expiration patent patent relating invokamet xr october janssen mtpc initiated patent infringement lawsuit united states district court district new jersey msn filed andas seeking approval market generic versions invokana invokamet xr expiration patent october janssen mtpc initiated patent infringement lawsuit united states district court district new jersey drl filed anda seeking approval market generic version invokamet expiration patent janssen mtpc entered settlement agreements prinston invagen june hetero july apotex teva august trial patents scheduled begin april trial patents scheduled begin may lawsuits janssen mtpc seeking order enjoining defendants marketing generic versions invokana invokamet andor invokamet xr expiration relevant patents opsumit january actelion pharmaceuticals ltd actelion initiated patent infringement lawsuit united states district court district new jersey zydus pharmaceuticals usa inc zydus amneal pharmaceuticals llc amneal filed anda seeking approval market generic version opsumit expiration united states patent patent lawsuit actelion seeking order enjoining zydus amneal marketing generic versions opsumit expiration patent amneal zydus stipulated infringement february actelion amneal entered settlement agreement trial zydus scheduled commence october july actelion pharmaceuticals ltd filed suit aurobindo pharma usa inc aurobindo pharma limited aurobindo aurobindo filed anda seeking approval market generic version opsumit expiration patent actelion seeking order enjoining defendants marketing generic version opsumit expiration patent trial aurobindo scheduled commence july invega sustenna january janssen pharmaceutica nv janssen pharmaceuticals inc collectively janssen initiated patent infringement lawsuit united states district court district new jersey teva pharmaceuticals usa inc teva filed anda seeking approval market generic version invega sustenna expiration united states patent trial scheduled begin june august janssen pharmaceutica nv janssen pharmaceuticals inc collectively janssen initiated patent infringement lawsuit united states district court district new jersey mylan laboratories limited mylan filed anda seeking approval market generic version invega sustenna expiration patent december janssen pharmaceutica nv janssen pharmaceuticals inc collectively janssen initiated patent infringement lawsuit united states district courts districts new jersey delaware pharmascience inc mallincrodt plc specgx llc collectively pharmascience filed anda seeking approval market generic version invega sustenna expiration united states patent february janssen inc janssen pharmaceutica nv collectively janssen initiated notices application section patented medicines notice compliance regulations teva canada limited teva minister health response teva 's filing abbreviated new drug submission ands seeking approval market generic version invega sustenna expiration canadian patent nos janssen seeking order prohibiting minister health issuing notice compliance respect tevas ands expiration patents final hearing scheduled begin february lawsuits janssen seeking order enjoining defendant marketing generic version invega sustenna expiration patentimbruvica beginning january pharmacyclics llc pharmacyclics janssen biotech inc jbi filed patent infringement lawsuits united states district court district delaware number generic companies filed andas seeking approval market generic versions imbruvica mg capsulesbefore expiration pharmacyclics united states patent nos andor relating imbruvica jbi exclusive licensee asserted patents following generic companies named defendants cipla limited cipla usa inc cipla fresenius kabi usa llc fresenius kabi usa inc fresenius kabi oncology limited fresenius kabi sandoz inc lek pharmaceuticals dd sandoz shilpa medicare limited shilpa sun pharma global fze sun pharmaceutical industries limited sun teva pharmaceuticals usa inc teva zydus worldwide dmcc cadila healthcare limited zydus trial scheduled begin october october pharmacyclics jbi filed patent infringement lawsuit united states district court district delaware sun asserting united states patent november pharmacyclics jbi filed patent infringement lawsuit united states district court district delaware hetero labs limited hetero labs limited unit hetero labs limited unitv hetero usa inc hetero filed anda seeking approval market generic version imbruvica mg capsules asserting infringement united states patent nos january pharmacyclics jbi amended complaints fresenius kabi zydus teva sandoz allege infringement us patent nos january pharmacyclics jbi filed patent infringement lawsuit united states district court district delaware zydus filed anda seeking approval market generic version imbruvica mg expiration us patent nos january pharmacyclics jbi filed patent infringement lawsuit united states district court district delaware hetero asserting infringement united states patent february pharmacyclics jbi amended complaints cipla shilpa sun allege infringement united states patent nos february pharmacyclics jbi entered settlement agreements teva hetero march pharmacyclics jbi entered settlement agreement shilpa march pharmacyclics jbi filed patent infringement lawsuit united states district court district delaware alvogen pine brook llc natco pharma ltd alvogen filed anda seeking approval market generic versions imbruvica tablets asserting infringement united states patent nos may pharmacyclics jbi amended complaints cipla allege infringement united states patent june pharmacyclics jbi amended complaints alvogen allege infringement united states patent august pharmacyclics jbi amended complaints cipla fresenius sandoz allege infringement us patent nos amended complaint sun allege infringement us patent march sandoz filed inter partes review ipr uspto seeking invalidate united states patent lawsuits pharmacyclics jbi seeking order enjoining defendants marketing generic versions imbruvica expiration relevant patentstracleer may actelion pharmaceuticals ltd actelion pharmaceuticals us inc initiated patent infringement lawsuit united states district court district new jersey natco pharma limited syneos health llc collectively natco filed anda seeking approval market generic version tracleer mg expiration us patent patent lawsuit actelion seeking order enjoining natco marketing generic version tracleer expiration patent november parties entered settlement agreement december actelion pharmaceuticals ltd actelion pharmaceuticals us inc initiated patent infringement lawsuit united states district court district new jersey zydus pharmaceuticals usa inc cadila healthcare limited collectively zydus filed anda seeking approval market generic version tracleer mg expiration us patent patent actelion seeking order enjoining zydus marketing generic version tracleer expiration patent risperdal consta july janssen pharmaceuticals inc alkermes pharma ireland limited alkermes controlled therapeutics inc initiated patent infringement lawsuit united states district court district delaware luye pharma group ltd luye pharma usa ltd nanjing luye pharmaceutical co ltd shandong luye pharmaceutical co ltd collectively luye filed anda seeking approval market generic version risperdal consta expiration united states patent november parties entered settlement lawsuit janssen seeking order enjoining luye marketing generic version risperdal consta expiration patent government proceedings like companies pharmaceutical consumer medical devices industries johnson johnson certain subsidiaries subject extensive regulation national state local government agencies united states countries operate result interaction government agencies ongoing significant litigation brought investigations conducted government agencies listed possible criminal charges substantial fines andor civil penalties damages could result government investigations litigation average wholesale price awp litigation johnson johnson several pharmaceutical subsidiaries jj awp defendants along numerous pharmaceutical companies named defendants series lawsuits state federal courts involving allegations pricing marketing certain pharmaceutical products amounted fraudulent otherwise actionable conduct among things companies allegedly reported inflated average wholesale price awp drugs issue payors alleged used awps calculating provider reimbursement levels plaintiffs cases included three classes private persons entities paid portion purchase drugs issue based awp state government entities made medicaid payments drugs issue based awp many cases federal actions state actions removed federal court consolidated pretrial purposes multidistrict litigation united states district court district massachusetts claims jj awp defendants ultimately dismissed jj awp defendants also prevailed case brought commonwealth pennsylvania awp cases resolved court order settlement case brought illinois settled trial new jersey putative class action based upon awp allegations pending centocor inc ortho biotech inc janssen biotech inc johnson johnson alza corporation cases resolved opioid litigation beginning continuing present johnson johnson janssen pharmaceuticals inc jpi along pharmaceutical companies named lawsuits brought certain state local governments related marketing opioids including duragesic nucynta nucynta er suits also raise allegations related previously owned active pharmaceutical ingredient supplier subsidiaries tasmanian alkaloids pty ltd noramco inc subsidiaries divested similar lawsuits also filed following groups plaintiffs individual plaintiffs behalf children suffering neonatal abstinence syndrome hospitals health insurerspayorsto date complaints pharmaceutical companies including johnson johnson jpi filed state attorneys general arkansas florida idaho illinois kentucky louisiana mississippi missouri new hampshire new jersey new mexico new york ohio oklahoma south dakota texas washington west virginia complaints manufacturers also filed state federal court city county local government agencies following states alabama arkansas california connecticut florida georgia illinois kentucky louisiana maine maryland massachusetts mississippi missouri nevada new hampshire new jersey new mexico new york north carolina ohio oklahoma oregon pennsylvania rhode island south carolina south dakota tennessee texas utah virginia washington west virginia wisconsin government puerto rico filed suit superior court san juan cases pending various state courts federal cases coordinated federal multidistrict litigation mdl pending us district court northern district ohio mdl addition province british columbia filed suit canada october antitrust complaint filed private plaintiffs federal court tennessee pending transfer mdl actions allege variety claims related opioid marketing practices including false advertising unfair competition public nuisance consumer fraud violations deceptive acts practices false claims unjust enrichment suits generally seek penalties andor injunctive monetary relief suits plaintiffs seeking joint several liability among defendants adverse judgment lawsuits could result imposition large monetary penalties significant damages including punitive damages cost abatement substantial fines equitable remedies sanctions trial matter filed oklahoma attorney general resulted judgment johnson johnson jpi amount million subject final order issued court court issued final judgment reducing amount million johnson johnson jpi appealed judgment company believes strong grounds overturn judgment october johnson johnson jpi announced settlement first case set trial mdl two counties ohio johnson johnson jpi pharmaceutical companies also received subpoenas requests information related opioids marketing practices following state attorneys general alaska indiana montana new hampshire south carolina tennessee texas washington september johnson johnson jpi contacted texas colorado attorney generals offices behalf approximately states regarding multistate attorney general investigation october company announced proposed agreement principle would include company paying billion settlement lawsuits subject various conditions agreement finalized agreement principle admission liability wrongdoing would resolve opioid lawsuits filed future claims states cities counties company predict agreement finalized individual cases ongoing including trial new york scheduled commence march august johnson johnson received grand jury subpoena united states attorneys office eastern district new york documents related companys antidiversion policies procedures distribution opioid medications company understands part broader investigation manufacturers distributors monitoring programs reporting controlled substances act september johnson johnson received subpoenas new york state department financial services nydfs part industrywide inquiry effect opioid prescriptions new york health insurance premiums company cooperating producing documents response various subpoenas requests information august depuy orthopaedics inc depuy inc known depuy synthes inc johnson johnson services inc collectively depuy received informal request united states attorney 's office district massachusetts civil division united states department justice united states production materials relating depuy asr xl hip device july united states notified united states district court district massachusetts declined intervene qui tam case filed pursuant false claims act companies february district court granted companies motion dismiss prejudice unsealed qui tam complaint denied qui tam relators request leave file amended complaint qui tam relators appealed case united states court appeals first circuit july first circuit affirmed district courts dismissal part reversed part affirmed decision deny relators request file third amended complaint relators remaining claims pending district court fact discovery currently scheduled close march october johnson johnson contacted california attorney general 's office regarding multistate attorney general investigation marketing surgical mesh products hernia urogynecological purposes johnson johnson 's subsidiary ethicon inc ethicon may california washington filed civil complaints johnson johnson ethicon ethicon us llc alleging violations consumer protection statutes april johnson johnson ethicon settled washington case california case started trial july concluded september january court found favor state awarded state civil penalties approximately million company intends appeal proceedings concluded trial court similar complaints filed companies kentucky august mississippi october west virginia september oregon december trial date kentucky case scheduled september adjourned new trial date scheduled october johnson johnson ethicon settled multistate investigation states district columbia december therakos inc therakos formerly subsidiary johnson johnson part orthoclinical diagnostics inc ocd franchise received letter civil division united states attorney 's office eastern district pennsylvania informing therakos united states attorney 's office investigating sales marketing uvadex methoxsalen uvar xts cellex systems period present united states attorney 's office requested ocd johnson johnson preserve documents could relate investigation therakos subsequently acquired affiliate gores capital partners iii lp january ocd divested june following divestiture ocd johnson johnson retains ocds portion liability may result investigation activity occurred prior sale therakos march march united states attorneys office requested johnson johnson produce certain documents johnson johnson cooperating requests june mississippi attorney general filed complaint chancery court first judicial district hinds county mississippi johnson johnson johnson johnson consumer companies inc known johnson johnson consumer inc jjci complaint alleges defendants violated mississippi consumer protection act failing disclose alleged health risks associated female consumers ' use talc contained johnson 's baby powder johnson 's shower shower product divested seeks injunctive monetary relief matter stayed pending interlocutory appeal december denial johnson johnson jjci 's motion summary judgment mississippi supreme court granted jj jjci 's request file interlocutory appeal denial motion summary judgment late soon establish briefing schedule company also received inquiries several state attorneys general march janssen pharmaceuticals inc jpi received civil investigative demand united states attorneys office southern district new york related jpis contractual relationships pharmacy benefit managers period january present regard certain jpi 's pharmaceutical products demand issued connection investigation false claims act july johnson johnson janssen products lp served qui tam complaint pursuant false claims act filed united states district court district new jersey alleging offlabel promotion two hiv products prezista intelence antikickback violations connection promotion products complaint filed seal december federal state governments declined intervene lawsuit prosecuted relators january janssen pharmaceuticals inc jpi received civil investigative demand united states department justice relating allegations concerning sales marketing practices olysio december johnson johnson jpi served whistleblower lawsuit filed united states district court central district california alleging offlabel promotion olysio additional products including nucynta xarelto levaquin remicade time federal state governments declined intervene lawsuit related civil investigative demand prosecuted former company employee united states district court central district california dismissed claim april may relator filed notice appeal united states court appeals ninth circuit january us court appeals ninth circuit dismissed relator 's appeal november second whistleblower lawsuit unsealed united states district court central district california lawsuit substantially similar lawsuit appeal brought name original relator federal state governments declined intervene second suit relator moved dismiss lawsuit without prejudice april court granted relator 's motion dismissed complaint without prejudice march janssen biotech inc received civil investigative demand united states department justice regarding false claims act investigation concerning management advisory services provided rheumatology gastroenterology practices purchased remicade simponi aria august unites states department ofjustice notified janssen biotech inc closing investigation january janssen biotech inc served newlyunsealed qui tam suit filed us district court district massachusetts april september johnson johnson received subpoenas united states attorney district massachusetts seeking documents broadly relating pharmaceutical copayment support programs darzalex olysio remicade simponi stelara zytiga subpoenas also seek documents relating average manufacturer price best price reporting center medicare medicaid services related products well rebate payments state medicaid agencies june johnson johnson received subpoena united states attorney 's office district massachusetts seeking information regarding practices pertaining sterilization depuy synthes inc spinal implants three hospitals boston well interactions employees company subsidiaries physicians hospitals johnson johnson depuy synthes inc produced documents response subpoena fully cooperating governments investigation july public prosecution service rio de janeiro representatives brazilian antitrust authority cade inspected offices companies including johnson johnson brasil indstria e comrcio de produtos para sade ltda authorities appear investigating allegations possible anticompetitive behavior possible improper payments medical device industry united states department justice united states securities exchange commission made additional inquiries johnson johnson brasil indstria e comrcio de produtos para sade ltda cooperating requests january new mexico attorney generals office filed suit johnson johnson johnson johnson consumer companies inc first judicial district court new mexico suit relates safety marketing companys talc products state included claims violations new mexico unfair practices act medicaid fraud act fraud taxpayers act fraud negligent misrepresentation negligence unjust enrichment state attorneys general informed company conducting inquiry matter time time company received requests variety united states congressional committees produce information relevant ongoing congressional inquiries policy johnson johnson cooperate inquiries producing requested information general litigation may two purported class actions filed federal court one united states district court central district california one united states district court southern district illinois johnson johnson johnson johnson consumer companies inc known johnson johnson consumer inc jjci alleging violations state consumer fraud statutes based nondisclosure alleged health risks associated talc contained johnson 's baby powder johnson 's shower shower product longer sold jjci cases seek injunctive relief monetary damages neither includes claim personal injuries october cases transferred united states district court district court new jersey part newly created federal multi district litigation july district court granted johnson johnson 's jjcis motion dismiss one cases september united states court appeals third circuit affirmed dismissal september plaintiff second case voluntarily dismissed complaint march plaintiff second case refiled illinois state court august united states customs border protection us cbp issued penalty notice janssen ortho llc janssen ortho assessing penalties alleged improper classification darunavir ethanolate active pharmaceutical ingredient prezista connection importation united states october janssen ortho submitted petition relief response penalty notice may us cbp issued amended penalty notice assessing substantial penalties janssen ortho filed petition relief july may us cbp issued mitigation decision determined janssen ortho negligently misrepresented darunavir ethanolate entitled duty free treatment june janssen ortho filed supplemental petition relief penalties proceeding impacted related classification litigation pending united states court international trade classification litigation determine whether darunavir ethanolate properly classified exempt duties upon importation united states trial classification litigation held july february court ruled darunavir ethanolate eligible duty free treatment march april putative class action complaints filed contact lens patients number courtsaround united states johnson johnson vision care inc jjvci contact lens manufacturers distributors retailers alleging vertical horizontal conspiracies fix retail prices contact lenses complaints allege manufacturers reached agreements certain distributors retailers concerning prices contact lenses could sold consumers plaintiffs seeking damages injunctive relief class action cases transferred united states district court middle district florida june plaintiffs filed consolidated class action complaint november december district court granted plaintiffs ' motion class certification defendants filed two motions interlocutory appeal class certification united states court appeals eleventh circuit motions denied defendants ' motions summary judgment denied november trial scheduled june august two thirdparty payors filed purported class action united states district court eastern district louisiana janssen research development llc janssen ortho llc janssen pharmaceuticals inc orthomcneil janssen pharmaceuticals inc johnson johnson well certain bayer entities alleging defendants improperly marketed promoted xarelto safer effective less expensive alternative medications failing fully disclose risks complaint seeks damages september pfizer inc pfizer filed antitrust complaint johnson johnson janssen biotech inc collectively janssen united states district court eastern district pennsylvania pfizer alleges janssen violated federal antitrust laws contracting strategies remicade complaint seeks damages injunctive relief discovery ongoing beginning september multiple purported class actions direct indirect purchasers filed johnson johnson janssen biotech inc collectively janssen alleging janssens remicade contracting strategies violated federal state antitrust consumer laws seeking damages injunctive relief november cases consolidated pretrial purposes united states district court eastern district pennsylvania remicade antitrust litigation motions dismiss denied direct indirect purchaser cases motion compel arbitration direct purchaser case denied district court united states court appeals third circuit reversed district court 's ruling june walgreen co kroger co filed antitrust complaint johnson johnson janssen biotech inc collectively janssen united states district court eastern district pennsylvania complaint alleges janssen violated federal antitrust laws contracting strategies remicade complaint seeks damages injunctive relief march summary judgment granted favor janssen ruling appeal united states court appeals third circuit june united states federal trade commission ftc issued civil investigative demand johnson johnson connection investigation whether janssens remicade contracting practices violate federal antitrust laws company produced documents information responsive civil investigative demand october certain united states service members families brought complaint number pharmaceutical medical devices companies including johnson johnson certain subsidiaries alleging defendants violated united states antiterrorism act complaint alleges defendants provided funding terrorist organizations sales practices pursuant pharmaceutical medical device contracts iraqi ministry health january plaintiffs ' motion file second amended complaint adding plaintiffs lawsuit granted april company moved dismiss second amended complaint october two separate putative class actions filed actelion pharmaceutical ltd actelion pharmaceuticals us inc actelion clinical research inc collectively actelion united states district court district maryland united states district court district columbia complaints allege actelion violated state federal antitrust unfair competition laws allegedly refusing supply generic pharmaceutical manufacturers samples tracleer tracleer subject risk evaluation mitigation strategy imposes restrictions distribution product january plaintiffs dismissed district columbia case filed consolidated complaint united states district court district maryland october court granted actelions motion dismiss amended complaint plaintiffs appealed decision december janssen biotech inc janssen oncology inc janssen research development llc johnson johnson collectively janssen served qui tam complaint filed behalf united states states district columbia complaint filed december united states district court northern district california alleges janssen violated federal false claims act state law providing pricinginformation zytiga government connection direct government sales governmentfunded drug reimbursement programs time federal state governments declined intervene case transferred united states district court district new jersey janssen moved dismiss complaint april blue cross blue shield louisiana hmo louisiana inc filed class action complaint janssen biotech inc janssen oncology inc janssen research development llc btg international limited united states district court eastern district virginia several additional complaints filed thereafter complaints generally allege defendants violated antitrust consumer protections laws several states sherman act pursuing patent litigation relating zytigain order delay generic entry case transferred united states district court district new jersey consolidated pretrial purposes may class action antitrust complaint filed janssen rd ireland janssen johnson johnson complaint alleges janssen violated federal state antitrust consumer protection laws agreeing exclusivity provisions agreements gilead concerning development marketing combination antiretroviral therapies cart treat hiv complaint also alleges gilead entered similar agreements bristolmyerssquibb japan tobacco case pending united states district court district northern california defendants filed motions dismiss complaint october innovative health llc filed complaint biosense webster inc bwi united statesdistrict court middle district california complaint alleges certain bwis business practices contractual terms violate antitrust laws united states state california restricting competition sale high density mapping catheters ultrasound catheters bwi filed motion dismiss complaint company received notices pfizer inc sanofi consumer health inc november boehringer ingelheim pharmaceuticals inc january tendering defense indemnification legal claims related personal injury matters putative class actions us canada related zantac ranitidine products notices based certain indemnification provisions regarding assumed liabilities connection stock asset purchase agreement pfizer inc company plaintiffs underlying suits allege generally zantac overthe counter ranitidine medications contain unsafe levels ndma nnitrosodimethylamine cause andor caused various cancers patients using products plaintiffs seeking injunctive monetary relief johnson johnson subsidiaries also parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund comparable state local foreign laws primary relief sought cost past andor future remediation restructuring company announced plans implement series actions across global supply chain intended focus resources increase investments critical capabilities technologies solutions necessary manufacture supply product portfolio enhance agility drive growth global supply chain actions include expanding use strategic collaborations bolstering initiatives reduce complexity improve costcompetitiveness enhance capabilities optimize supply chain network additional details global supply chain restructuring strategic collaborations see note consolidated financial statements company recorded pretax charge billion included following lines consolidated statement earnings billion restructuring billion income expense billion cost products sold total project costs approximately billion recorded since restructuring announced see following table additional details restructuring program total company expects global supply chain actions generate approximately billion billion annual pretax cost savings substantially delivered company expects record pretax restructuring charges approximately billion billion year period activity costs associated network optimizations exit costs accelerated depreciation amortization following table summarizes severance charges associated spending initiatives fiscal year ended severance asset writeoffs total dollars millions reserve balance december activity reserve balance december current year activity charges cash payments settled non cash reserve balance december cash outlays severance expected substantially paid next years accordance company 's plans local laws includes project expense salaries employees supporting initiatives consulting expenses relates pension related actuarial losses associated transfer employees jabil inc part strategic collaboration company continuously reevaluates severance reserves related restructuring timing payments due planned release associates regarding several longerterm projects company believes existing severance reserves sufficient cover global supply chain plans given period actions take place company continue assess make adjustments necessary additional amounts become probable estimable report independent registered public accounting firm board directors shareholders johnson johnson opinions financial statements internal control financial reporting audited accompanying consolidated balance sheets johnson johnson subsidiaries company december december related consolidated statements earnings comprehensive income equity cash flows three fiscal years period ended december including related notes collectively referred consolidated financial statements also audited company 's internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso opinion consolidated financial statements referred present fairly material respects financial position company december december results operations cash flows three fiscal years period ended december conformity accounting principles generally accepted united states america also opinion company maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued coso basis opinions company 's management responsible consolidated financial statements maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying management 's report internal control financial reporting responsibility express opinions companys consolidated financial statements company 's internal control financial reporting based audits public accounting firm registered public company accounting oversight board united states pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audits accordance standards pcaob standards require plan perform audits obtain reasonable assurance whether consolidated financial statements free material misstatement whether due error fraud whether effective internal control financial reporting maintained material respects audits consolidated financial statements included performing procedures assess risks material misstatement consolidated financial statements whether due error fraud performing procedures respond risks procedures included examining test basis evidence regarding amounts disclosures consolidated financial statements audits also included evaluating accounting principles used significant estimates made management well evaluating overall presentation consolidated financial statements audit internal control financial reporting included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk audits also included performing procedures considered necessary circumstances believe audits provide reasonable basis opinions described managements report internal control financial reporting management excluded ciz holdings co ltd dr cilabo assessment internal control financial reporting december acquired company business combination also excluded dr cilabo audit internal control financial reporting dr cilabo whollyowned subsidiary whose total assets excluding intangible assets goodwill total sales excluded managements assessment audit internal control financial reporting represent less related consolidated financial statement amounts fiscal year ended december definition limitations internal control financial reporting companys internal control financial reporting process designed provide reasonable assurance regarding thereliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company ii provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company iii provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate critical audit matters critical audit matters communicated matters arising current period audit consolidated financial statements communicated required communicated audit committee relate accounts disclosures material consolidated financial statements ii involved especially challenging subjective complex judgments communication critical audit matters alter way opinion consolidated financial statements taken whole communicating critical audit matters providing separate opinions critical audit matters accounts disclosures relate us pharmaceutical rebate reserves managed care medicare medicaid described note consolidated financial statements company recognizes revenue product sales obligations terms contract customer satisfied rebates discounts provided customers accounted variable consideration recorded reduction sales liability rebates discounts recognized within accrued rebates returns promotions consolidated balance sheet significant portion liability related rebates sale pharmaceutical goods within us primarily managed care medicare medicaid programs amounted billion december significant rebate programs include us managed care medicare medicaid rebate programs rebates discounts estimated management based contractual terms historical experience patient outcomes trend analysis projected market conditions us pharmaceutical market principal considerations determination performing procedures relating us pharmaceutical rebate reserves managed care medicare medicaid critical audit matter use significant judgment management due significant measurement uncertainty involved developing reserves turn led high degree auditor judgment subjectivity audit effort applying procedures assumptions related contractual terms customers historical experience patient outcomes trend analysis projected market conditions us addressing matter involved performing procedures evaluating audit evidence connection forming overall opinion consolidated financial statements procedures included testing effectiveness controls relating us pharmaceutical rebate reserves managed care medicare medicaid including controls assumptions used estimate rebates procedures also included among others developing independent estimate rebates utilizing third party information price market conditions us terms specific rebate programs historical trend actual rebate claims paid ii testing rebate claims processed company including evaluating claims consistency contractual mandated terms companys rebate arrangements iii comparing independent estimate managements estimates litigation contingencies talc described notes consolidated financial statements company records accruals loss contingencies associated legal matters including talc probable liability incurred amount loss reasonably estimated extent adverse verdicts rendered company management record accrual loss determined probable reasonably estimated matters management unable estimate reasonably possible loss range loss ability make estimates judgments affected various factors including among things whether damages sought proceedings unsubstantiated indeterminate scientific legal discovery commenced complete proceedings early stages matters present legal uncertainties significant facts dispute procedural jurisdictional issues uncertainty unpredictability thenumber potential claims numerous parties involved verdicts company matter including verdict july billion described management company believes strong grounds appeal overturn verdicts company established accrual primarily defense costsin connection product liability litigation associated body powders containing talc principal considerations determination performing procedures relating talc litigation critical audit matter use significant judgment management assessing likelihood loss incurred managements determination whether reasonable estimate loss range loss claim made turn led high degree auditor judgment effort evaluating managements assessment loss contingencies associated litigation addressing matter involved performing procedures evaluating audit evidence connection forming overall opinion consolidated financial statements procedures included testing effectiveness controls relating managements evaluation talc litigation including controls determining whether loss probable whether amount loss reasonably estimated well financial statement disclosures procedures also included among others gaining understanding companys process around accounting reporting talc litigation ii discussing status significant known actual potential litigation companys inhouse legal counsel well external counsel deemed necessary iii obtaining evaluating letters audit inquiry internal external legal counsel significant litigation iv evaluating reasonableness managements assessment regarding whether unfavorable outcome reasonably possible probable reasonably estimable v evaluating sufficiency companys litigation contingencies disclosures litigation opioids described notes consolidated financial statements company records accruals loss contingencies associated legal matters including opioids probable liability incurred amount loss reasonably estimated extent adverse verdicts rendered company management record accrual loss determined probable reasonably estimated matters management unable estimate reasonably possible loss range loss amounts accrued legal contingencies often result complex series judgments future events uncertainties rely heavily estimates assumptions including timing related payments ability make estimates judgments affected various factors including among things whether damages sought proceedings unsubstantiated indeterminate matters present legal uncertainties significant facts dispute procedural jurisdictional issues uncertainty unpredictability number potential claims numerous parties involved company named numerous lawsuits brought certain state local governments related opioids matters trial matter filed oklahoma attorney general resulted judgment company amount million subsequently reduced million company appealed judgment described management believes strong grounds overturn judgment separately october company announced proposed agreement principle would include company paying billion settlement lawsuits subject various conditions agreement finalized company predict agreement finalized company recorded pretax charge billion fiscal year ended december matter principal considerations determination performing procedures relating opioids litigation critical audit matter use significant judgment management assessing likelihood loss incurred judgment company oklahoma managements determination whether reasonable estimate range loss proposed agreement principle settle opioids litigation made turn led high degree auditor judgment effort evaluating managements assessment loss contingencies associated litigation addressing matter involved performing procedures evaluating audit evidence connection forming overall opinion consolidated financial statements procedures included testing effectiveness controls relating managements evaluation opioid litigation including controls determining whether loss probable whether amount loss reasonably estimated well financial statement disclosures procedures also included among others gaining understanding companys process around accounting reporting opioids litigation ii discussing status significant known actual potential litigation ongoing settlement negotiations companys inhouse legal counsel well external counsel deemed necessary iii obtaining evaluating letters audit inquiry internal external legal counsel significant litigation iv evaluating reasonableness managements assessment regarding whether unfavorable outcome reasonably possible probable reasonably estimable v evaluating sufficiency companys litigation contingencies disclosuress pricewaterhousecoopers llp florham park new jersey february served companys auditor since least able determine specific year began serving auditor company managements report internal control financial reporting section sarbanesoxley act management required assess effectiveness companys internal control financial reporting end fiscal year report based assessment whether companys internal control financial reporting effective management company responsible establishing maintaining adequate internal control financial reporting companys internal control financial reporting designed provide reasonable assurance reliability companys financial reporting preparation external financial statements accordance generally accepted accounting principles internal controls financial reporting matter well designed inherent limitations therefore internal control financial reporting determined effective provide reasonable assurance respect financial statement preparation may prevent detect misstatements moreover projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate companys management assessed effectiveness companys internal control financial reporting december making assessment company used criteria established committee sponsoring organizations treadway commission coso internal controlintegrated framework criteria areas control environment risk assessment control activities information communication monitoring companys assessment included extensive documenting evaluating testing design operating effectiveness internal controls financial reporting company acquired ciz holdings co ltd dr cilabo business combination january dr cilabo 's total assets excluding intangible assets goodwill total sales represented less related consolidated financial statement amounts fiscal year ended december acquisition occurred fiscal year scope company 's assessment design effectiveness internal control financial reporting fiscal year excluded mentioned acquisition exclusion accordance sec 's general guidance assessment recently acquired business may omitted scope year acquisition based companys processes assessment described management concluded december companys internal control financial reporting effective effectiveness companys internal control financial reporting december audited pricewaterhousecoopers llp independent registered public accounting firm stated report appears herein alex gorsky joseph j wolk alex gorsky joseph j wolk chairman board directors executive vice president chief financial officer chief executive officer shareholder return performance graphs set forth line graphs comparing cumulative total shareholder return companys common stock periods five years ten years ending december cumulative total return standard poors stock index standard poors pharmaceutical index standard poors health care equipment index graphs tables assume invested december december companys common stock standard poors stock index standard poors pharmaceutical index standard poors health care equipment index dividends reinvested year shareholder return performance jj vs indices johnson johnson sp index sp pharmaceutical index sp healthcare equipment index year shareholder return performance jj vs indices johnson johnson sp index sp pharmaceutical index sp healthcare equipment index item changes disagreements accountants accounting financial disclosure applicable item controls procedures disclosure controls procedures end period covered report company evaluated effectiveness design operation disclosure controls procedures companys disclosure controls procedures designed ensure information required disclosed company reports files submits exchange act recorded processed summarized reported within time periods specified secs rules forms disclosure controls procedures include without limitation controls procedures designed ensure information required disclosed company reports files submits exchange act accumulated communicated companys management including principal executive principal financial officers persons performing similar functions appropriate allow timely decisions regarding required disclosure alex gorsky chairman chief executive officer joseph j wolk executive vice president chief financial officer reviewed participated evaluation based evaluation messrs gorsky wolk concluded end period covered report companys disclosure controls procedures effective reports internal control financial reporting information called item incorporated herein reference managements report internal control financial reporting attestation regarding internal controls financial reporting included report independent registered public accounting firm included item report changes internal control financial reporting fiscal quarter ended december changes companys internal control financial reporting identified connection evaluation required rules exchange act materially affected reasonably likely materially affect companys internal control financial reporting company implementing multiyear enterprisewide initiative integrate simplify standardize processes systems human resources information technology procurement supply chain finance functions enhancements support growth companys financial shared service capabilities standardize financial systems initiative response identified deficiency weakness companys internal control financial reporting response initiative company continue align streamline design operation financial control environment item b information applicable part iii item directors executive officers corporate governance information called item incorporated herein reference discussion audit committee caption item election directors board committees material captions item election directors stock ownership section compliance delinquent section reports proxy statement material caption executive officers registrant part report companys code business conduct covers employees including chief executive officer chief financial officer controller meets requirements sec rules promulgated section sarbanesoxley act code business conduct available companys website wwwjnjcomcode ofbusinessconduct copies available shareholders without charge upon written request secretary companys principal executive offices substantive amendment code business conduct waiver code granted chief executive officer chief financial officer controller posted companys website wwwinvestorjnjcomgovcfm within five business days retained website least one year addition company adopted code business conduct ethics members board directors executive officers code business conduct ethics members board directors executive officers available companys website wwwinvestorjnjcomgovboardconductcfm copies available shareholders without charge upon written request secretary companys principal executive offices substantive amendmentto code waiver code granted member board directors executive officer posted companys website wwwinvestorjnjcomgovcfm within five business days retained website least one year item executive compensation information called item incorporated herein reference material captions item election directors director compensation item compensation committee report compensation discussion analysis executive compensation tables proxy statement material incorporated herein reference material caption compensation committee report proxy statement shall deemed furnished filed report shall deemed incorporated reference filing securities act amended securities exchange act amended result furnishing except extent company specifically incorporates reference item security ownership certain beneficial owners management related stockholder matters information called item incorporated herein reference material caption item stock ownership section compliance proxy statement note common stock stock option plans stock compensation agreements notes consolidated financial statements item report equity compensation plan information following table provides certain information december concerning shares companys common stock may issued existing equity compensation plans number securities weighted issued upon average exercise exercise price number securities outstanding outstanding remaining available options options future issuance equity plan category rights rights compensation plans equity compensation plans approved security holders equity compensation plans approved security holders total included category following equity compensation plans approved companys shareholders longterm incentive plan longterm incentive plan column excludes shares reflected column number securities issued upon exercise outstanding options rights longterm incentive plan expired april options restricted shares granted subsequent date longterm incentive plan item certain relationships related transactions director independence information called item incorporated herein reference material captions item election directors director independence related person transactions proxy statement item principal accountant fees services information called item incorporated herein reference material caption item ratification appointment independent registered public accounting firm proxy statement part iv item exhibits financial statement schedules following documents filed part report financial statements consolidated balance sheets end fiscal years consolidated statements earnings fiscal years consolidated statements comprehensive income fiscal years consolidated statements equity fiscal years consolidated statements cash flows fiscal years notes consolidated financial statements report independent registered public accounting firm schedules omitted applicable required information included financial statements notes exhibits required filed item l regulation sk information called item incorporated herein reference exhibit index report item summary registrants may voluntarily include summary information required item company elected include summary information signatures pursuant requirements section securities exchange act registrant duly caused report signed behalf undersigned thereunto duly authorized date february johnson johnson registrant gorsky gorsky chairman board directors chief executive officer pursuant requirements securities exchange act report signed following persons behalf registrant capacities dates indicated signature title date gorsky chairman board directors february gorsky chief executive officer principal executive officer chief financial officer j j wolk february j j wolk principal financial officer controller chief accounting officer r j decker jr february r j decker jr principal accounting officer director c beckerle february c beckerle director davis february davis director e l davis february e l davis director j doudna february j doudna signature title date hewson director february hewson h joly director february h joly b mcclellan director february b mcclellan director mulcahy february mulcahy director w perez february w perez director c prince february c prince director e washington february e washington director weinberger february weinberger director r williams february r williams exhibit index reg sk exhibit table description item exhibit restated certificate incorporation effective february incorporated herein reference exhibit registrants annual report fiscal year ended january ii bylaws company amended effective january incorporated herein reference exhibit registrants form k current report filed january upon request securities exchange commission registrant furnish copy instruments defining rights holders longterm debt registrant longterm incentive plan incorporated herein reference exhibit registrants registration statement filed commission may file b form stock option certificate longterm incentive plan incorporated herein reference exhibit registrants form k current report filed january c longterm incentive plan incorporated herein reference appendix registrants proxy statement filed commission march form stock option certificate restricted share unit certificate performance share unit certificate longterm incentive plan incorporated herein reference